A ROLE FOR EPAC1 AND EPAC2 IN NOCICEPTOR HYPEREXCITABILITY AND CHRONIC PAIN AFTER SPINAL CORD INJURY by Berkey, Samantha
Texas Medical Center Library
DigitalCommons@TMC
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
12-2018
A ROLE FOR EPAC1 AND EPAC2 IN
NOCICEPTOR HYPEREXCITABILITY AND
CHRONIC PAIN AFTER SPINAL CORD
INJURY
Samantha Berkey
Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Animal Studies Commons, Biochemistry Commons, Medicine and Health Sciences
Commons, and the Neuroscience and Neurobiology Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has
been accepted for inclusion in UT GSBS Dissertations and Theses (Open
Access) by an authorized administrator of DigitalCommons@TMC. For
more information, please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Berkey, Samantha, "A ROLE FOR EPAC1 AND EPAC2 IN NOCICEPTOR HYPEREXCITABILITY AND CHRONIC PAIN
AFTER SPINAL CORD INJURY" (2018). UT GSBS Dissertations and Theses (Open Access). 914.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/914
 
 
i 
 
A ROLE FOR EPAC1 AND EPAC2 IN NOCICEPTOR HYPEREXCITABILITY AND 
CHRONIC PAIN AFTER SPINAL CORD INJURY 
 
By 
Samantha Claire Berkey 
APPROVED: 
_________________________ 
Dr. Carmen W. Dessauer 
Advisory Professor 
 
_________________________ 
Dr. Xiaodong Cheng 
Advisory Professor 
 
_________________________ 
Dr. Edgar T. Walters 
 
_________________________ 
Dr. Swathi Arur 
 
_________________________ 
Dr. Shane R. Cunha 
 
_________________________ 
Dr. Juan J. Herrera 
___________________________________________________________________________ 
Approved: 
_________________________ 
Dean,  
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of 
Biomedical Sciences 
A ROLE FOR EPAC1 AND EPAC2 IN NOCICEPTOR HYPEREXCITABILITY AND 
CHRONIC PAIN AFTER SPINAL CORD INJURY 
 
A 
THESIS 
Presented to the Faculty of 
The University of Texas 
MD Anderson Cancer Center UTHealth 
Graduate School of Biomedical Sciences 
in Partial Fulfillment 
of the Requirements 
for the Degree of 
DOCTOR OF PHILOSOPHY 
 
By 
Samantha Claire Berkey 
Houston, Texas 
December, 2018
 
 
iii 
 
Dedication 
 
This is for the people I love, who have stood by me through all the ups and downs… 
 
 My Dad Richard  
My Mother Jackie and Stepdad Joe 
Laura and Katie, my two favorite sisters 
Shaun, who has seen the grad student process up close and still loves me…  
The whole Houston family I am now a part of, especially Helen, Stanley, and Boobie 
My Houston friends, who have always risen to the occasion, whether at a bar or hospital 
And the new friends I have made here, who have quickly become lifelong 
 
To quote one of you: 
“Finally” 
 
 
 
  
 
iv 
 
Acknowledgements 
 
I would like to thank Dr. Carmen W. Dessauer for her mentorship and expertise. Her 
incredible support and wealth of knowledge have allowed me to reach this point. She accepts 
nothing but the best from her students, and that has produced a thesis I am proud to present. 
I would also like to thank my co-mentor, Dr. Xiaodong Cheng, for his helpful advice and 
never-ending support for my project. He is always ready to discuss scientific ideas or provide 
technical assistance.  
Additionally I would like to thank the other members of my committee, Drs. Edgar T. 
Walters, Swathi Arur, Shane Cunha, and Juan J. Herrera. Besides advising and guiding this 
thesis project, each has offered continued support and resources. Thank you to Dr. Walters 
for helping introduce me to the complex field of animal behavior, and allowing me an 
incredible amount of access to all of his behavior equipment and his SCI rat model. Thank 
you to Dr. Arur for joining me at the very beginning of this graduate school experience, and 
sticking with me until the end. Thank you to Dr. Cunha for being an incredible source of 
knowledge and moral support, as well as for hosting impromptu journal clubs to increase 
students’ exposure to subjects outside their field. And thank you to Dr. Herrera, who not only 
served on my committee, but without whom this work would have been impossible. Thank 
you for the massive number of surgeries you performed for this project, as well as your 
endless supply of assistance with animal care and activity box experiments. 
Thank you to Dr. Alexis Bavencoffe, for not only performing all of the electrophysiology 
experiments, but also instructing me on how to interpret and analyze their meaning.  
v 
 
Thank you to Dr. Fang C. Mei, who always patiently shared her time to help with large and 
minute aspects of this project, including breeding and sharing the EPAC mice and 
troubleshooting western techniques with me. Thank you to Dr. Annemieke Kavelaars and 
Vicky Ma, for taking the time to teach me proper von Frey technique. 
I also sincerely thank all of my lab members. Thank you Dr. Yong Li for tirelessly answering 
my questions, as well as keeping an encyclopedic knowledge of everything in the lab and its 
location. Thank you Yan Wang for teaching me how to be a mouse whisperer, and for always 
offering to lend your amazing tissue collection skills. Thank you to Wei Yu, who has made it 
so I always seem to have exactly what I need when I need it. Thank you to Dr. Anibal Garza 
Carbajal for sharing your knowledge and advice, especially in regards to signaling pathways 
and robotic techniques. Thank you to Simran Rahman, who was absolutely indispensable to 
the animal work. Thank you to Tanya Baldwin, my fellow graduate student, who is a 
limitless source of help, support, and general happiness. 
Thank you to the members of the Cheng lab, Drs. Yingmin Zhu, Hui Chang, Will Robichaux, 
Upsana Banerjee, Wei Ling, and Wenli Yang, for all of your assistance and help throughout 
the years. Thank you to the members of the Walters lab, Max A. Odem, Elia Lopez, Guo-
Ying Xu, Kendra Wicks, and Emily, who were always willing to share techniques and 
discuss results. A special thanks to Max, who would endlessly discuss animal behavior, and 
was my guide in designing the behavioral aspects of this project. 
Thank you to Dr. Eric Swindell, who introduced me to the fun of science. He believed in and 
supported my scientific career when I needed it most, and still does. 
vi 
 
Thank you to all the faculty and administrators in the IBP program. You do a fantastic job. 
Lastly, thank you to all of my fellow students and friends in the program and Houston. You 
are an amazing support system and I couldn’t have done it without you.  
  
vii 
 
A ROLE FOR EPAC1 AND EPAC2 IN NOCICEPTOR HYPEREXCITABILITY AND 
CHRONIC PAIN AFTER SPINAL CORD INJURY 
Samantha Claire Berkey 
Advisory Professor: Dr. Carmen W. Dessauer and Dr. Xiaodong Cheng 
 
Chronic pain is a major complaint of those living with spinal cord injury (SCI), 
affecting 65-80% of the SCI population, but the treatment options remain limited or non-
existent. The cAMP sensor EPAC has previously been shown to play a key role in chronic 
inflammatory and neuropathic pain, though the contribution from each of its two main 
isoforms, EPAC1 and EPAC2, is unclear. Here I test the hypothesis that both EPAC1 and 
EPAC2 play a key role in the maintenance of persistent nociceptor hyperexcitability and 
chronic pain after SCI.  
Using both a T9 SCI mouse model and a T10 SCI rat model, we employed behavior 
assays and electrophysiological techniques to characterize the role of EPAC1 and 2 in SCI-
induced pain. We also used three novel methods: the operant mechanical conflict test (MC) 
behavior test, an electrophysiological measure of ongoing activity (OA), and analysis of the 
transient depolarizing fluctuations (DSFs) in membrane potential that contribute to nociceptor 
excitability. 
After SCI, we observed a significant increase in the incidence of SA, large DSFs, and 
OA in WT, Epac2-/-, and Epac1-/- mice. The SCI-induced increase in SA and OA incidence 
could be significantly decreased in nociceptors isolated from Epac1-/- and Epac2-/- mice by 
inhibition of the complementary EPAC isoform. Behavioral measures of “pain” did not show 
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significant differences between WT and EPAC2-/- mice in a naïve state or after injury. 
Additionally, multi-day treatment with ESI-09, an inhibitor of both Epac1 and 2, caused a 
significant decrease in mechanical sensitivity within WT and Epac2-/- mice; however, in vitro 
treatment with ESI-09 resulted in mass electrophysiological silencing of nociceptors, 
suggesting the decrease in sensitivity was due to nociceptor cell silencing in vivo.  
The data shows compensatory and/or redundant functions for EPAC1 and EPAC2. 
Importantly, future studies and attempts to develop chronic pain therapies may need to account 
for both isoforms of EPAC and their complementary roles.  
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Chapter 1: Introduction 
The ability to feel pain and detect noxious stimuli is essential for survival and well-being. 
Acute pain serves as a warning system; tissue or nerve damage sensitizes an injured area, 
helping to promote wound guarding and avoidance behavior during recovery.  However, the 
mechanisms underlying normal pain can become permanently altered, such that 
hypersensitivity does not resolve after the injury heals, and instead becomes debilitating 
chronic pain. Chronic pain affects 65-80% of those living with spinal cord injury (SCI), but 
the treatment options remain limited or non-existent (Siddall et al., 2003).  
Spinal cord injury has multiple devastating physiological and psychological impacts, but 
the management of chronic pain is often cited as the leading factor in determining life 
satisfaction (van Leeuwen et al., 2012, Finnerup, 2013). Chronic pain after SCI can include 
nociceptive (Finnerup et al., 2008), neuropathic (Norrbrink Budh et al., 2003, Siddall et al., 
2003, Werhagen et al., 2004), or additional “other” or “unknown” pain, as classified by the 
International Spinal Cord Injury Pain (ISCIP) Classification group (Bryce et al., 2011). The 
ISCIP attempts to classify SCI by pain type, subtype, and source in attempt to develop better 
treatment options, and this classification highlights how challenging SCI is to treat, as patients 
experience different combinations of initial trauma and acute and chronic pain states. Current 
therapies include attempting to treat secondary symptoms (such as inflammation or muscle 
weakness), the use of analgesics or opioids, and complementary behavioral programs for 
coping with pain, all of which simply manage pain (Heutink et al., 2012, Löfgren and 
Norrbrink, 2012). In order to develop more effective therapies, a deeper understanding of the 
mechanisms underlying normal, “acute” pain, as well as the transition to and maintenance of 
chronic pain is required. 
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1.1 A Brief Introduction to Pain Processing 
Nociception is the detection of intense thermal, mechanical, or chemical stimuli by a 
subpopulation of peripheral nerve fibers, or nociceptors (Basbaum et al., 2009). Nociceptor 
cell bodies are located in the dorsal root ganglia (DRG in the body; trigeminal ganglion in the 
face), and innervate their target organ and the spinal cord or brainstem with a peripheral and 
central axonal branch, respectively. The central and peripheral axonal branches contain similar 
distributions of proteins generated in the cell body making nociceptors pseudo-unipolar. 
Importantly, nociceptors are only activated when a stimulus reaches a certain intensity, a 
threshold meant to ensure only stimuli in the noxious range result in nociception. The 
biophysical and molecular properties that allow this selective response are important 
mechanisms in pain signaling, as alterations lead to a lower pain threshold. The pseudo-
unipolarity of nociceptors can also affect the threshold, as it allows endogenous molecules, 
such as inflammatory mediators or neurotransmitters, to target both terminals to affect 
sensitivity (Basbaum et al., 2009).  
Nociceptors can be classified by neuroanatomical and molecular characteristics (Snider 
and McMahon, 1998).  Anatomically, nociceptors consists of two major classes, which are 
composed of heterogeneous populations. The first class includes the Aδ fibers, which are thinly 
myelinated, medium diameter afferents that mediate acute, fast pain and can be further 
subdivided into Type I high threshold mechanical (HTM) and Type II fibers: Type I HTM Aδ 
Fibers are responsible for the immediate acute response to noxious mechanical stimuli, Type 
II mediate the immediate response to noxious heat  (It is worth mentioning there are also large 
diameter, fast-conducting, myelinated Aβ fibers, but these mainly respond to innocuous 
mechanical stimuli). The second class includes unmyelinated, small diameter C-fibers that 
conduct slow, poorly localized pain. C-fibers are often polymodal, and can be additionally 
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classified as peptidergic or non-peptidergic.  Peptidergic C-fibers synthesize and release 
neuropeptides, such as substance P and calcitonin-gene related protein (CGRP), and respond 
to nerve growth factor (NGF) through expression of the neurotrophin receptor TrkA (Snider 
and McMahon, 1998, Chao, 2003). The non-peptidergic population, which bind isolectin B4 
(IB4), responds to glial-derived neurotrophic factors (GDNF) through the c-Ret neurotrophin 
receptor, and express the purinergic P2X3 receptor, an ATP gated ion channel (Snider and 
McMahon, 1998).  
During normal acute pain responses, a noxious stimulus is detected by the Aδ or C-fiber’s 
peripheral free nerve ending. More specifically, the noxious stimulus is detected by the 
multiple ion channels and receptors embedded in the plasma membrane of the Aδ or C-fiber’s 
peripheral free nerve ending (Figure 1), which become active allowing ion channels to open 
and the membrane to depolarize, generating a receptor potential. These receptors include the 
TRP channels (TRPV1-4, TRPA1, TRPM8); TRPV1 responds to noxious heat, as well as 
capsaicin, and is most abundantly expressed in nociceptors, which allows a capsaicin positive 
response to be used to identify nociceptors (Caterina et al., 2000, Lauria et al., 2006).  
Additional TRP channels are also involved in temperature sensing, such as TRPV2 which 
responds to higher noxious heat temperatures and is predominantly expressed in Aδ fibers 
(Leffler et al., 2007, Rau et al., 2007), and TRPA1, which responds to noxious cold and 
chemical irritants such as mustard oil or garlic (Bandell et al., 2004, Jordt et al., 2004).  
Identification of mechanoreceptors, which respond to noxious mechanical stimuli such as 
intense pressure, stress, or visceral pain, has been slightly more challenging, but is likely to 
include some of the TRP channels and the Piezo2 ion channels (Ranade et al., 2015). 
Importantly, there are also chemoreceptors, which can factor in acute pain, but play a major 
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role in responding to endogenous factors released after tissue injury. The presence or absence 
of certain ion channels or receptors is what allows nociceptors to be poly- or unimodal.  
After a receptor potential is generated, the signal is propagated along the axon, through the 
nociceptor cell body, or DRG, and onward along the axon innervating the spinal cord dorsal 
horn. The fast acting voltage gated Na+, K+, and Ca2+ and hyperpolarization-activated, cation 
non-selective (HCN) channels propagate the action potential, but can also modify the signal to 
influence nociception.  The NaV channels can be tetrodotoxin (TTX) sensitive or resistant, and 
are expressed predominantly in small-diameter nociceptors. Of interest is the Nav1.7 channel, 
where a loss of function leads to congenital insensitivity to pain (Cox et al., 2006, Fischer and 
Waxman, 2010), and the Nav1.8 channel, which plays a role in chronic nociceptor excitability 
and pain-behavior after SCI (discussed below) (Yang et al., 2014) .  
From the DRG, central processes form excitatory synapses with second order neurons in 
laminae I, II, and V of the dorsal horn, which project via the spinothalamic and 
spinoreticulothalamic relays to the thalamus and brainstem, and finally to cortical structures, 
where the noxious signal is processed as the complex emotional experience of “pain” (Millan, 
1999). There are also descending, inhibitory pathways that arise in the brainstem, 
hypothalamus, and cortical structures, that may modulate inputs from primary afferent and 
second order neurons (Millan, 2002).   
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Figure 1. Noxious stimuli are detected by Aδ or C-fibers, specifically by the multiple ion 
channels and receptors embedded in the plasma membrane of the Aδ or C-fiber’s peripheral 
free nerve ending. Specific ion channels and receptors respond to thermal, mechanical, and/or 
chemical stimuli, to generate a receptor potential. This signal is propagated by the fast acting 
voltage gated Na+, K+, and Ca2+ and hyperpolarization-activated, cation non-selective (HCN) 
channels along the axon, to the DRG, and onward to the CNS.  
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1.2 The Role of Peripheral Sensitization in Chronic Pain after SCI 
After SCI, the mechanisms underlying normal pain become permanently altered, such that 
the hypersensitivity does not resolve, and instead becomes debilitating chronic pain. Many 
studies focus on alterations in excitability within central neurons at the spinal and supraspinal 
levels after SCI, such as gliosis (Detloff et al., 2008) or loss of descending, inhibitory 
(GABAergic) tone (Meisner et al., 2010), which contribute to the maintenance of at-level and 
below level chronic neuropathic pain after SCI. However, there is increasing recognition that 
persistent alterations within the peripheral nervous system, specifically a switch in nociceptors 
within DRG at and below the contusion level to a persistent, hyperexcitable state, contribute 
to SCI-induced chronic pain (Bedi et al., 2010, Walters, 2012, Yang et al., 2014). This 
continuous enhanced input from peripheral primary sensory neurons to spinal pain pathways 
contributes to central sensitization and is correlated with an increase in pain-like behaviors 
within animal models (Bedi et al., 2010, Walters, 2012, Yang et al., 2014). Interestingly, this 
same phenomenon is observed in peripheral injury models (Burchiel et al., 1985, Djouhri et 
al., 2001, Xiao and Bennett, 2007, Xu and Brennan, 2010) and leads to similar central 
sensitization (Gracely et al., 1992, Xie et al., 2005, Pitcher and Henry, 2008). 
The first evidence for the potential contribution of peripheral nociceptors came from 
multiple pre-clinical models of SCI; the authors found SCI-induced sprouting of CGRP+ C-
fibers within spinal dorsal horn segments below the injury site (Christensen and Hulsebosch, 
1997, Ondarza et al., 2003, Ackery et al., 2007, Zinck et al., 2007, Hou et al., 2009, Lee-Kubli 
et al., 2016). In vivo injection of antibody against the growth factor NGF could inhibit this 
central expansion of C-fibers, but, more interestingly, also ameliorated the SCI-induced pain 
(Christensen and Hulsebosch, 1997).  
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Besides just expanding the number of central peptidergic fibers, in vivo work showed SCI 
enhanced the sensitivity and firing rates of C-fiber neurons, inducing spontaneous activity (SA) 
within both the peripheral terminals and the somata located within the DRG (Carlton et al., 
2009, Bedi et al., 2010). This hyperactive, spontaneously active state can be observed between 
3 days and 6 months post injury, and is driven by the combined effects of three nociceptor 
intrinsic mechanisms: sustained depolarization of resting membrane potential (RMP), a 
decrease in action potential threshold, and an increase in amplitudes of depolarizing 
spontaneous fluctuations (DSF) (Figure 2) (Odem et al., 2018). Additionally, these mechanism 
can potentiate ongoing activity (OA) in nociceptors driven by extrinsic signals (Bedi et al., 
2010, Yang et al., 2014, Odem et al., 2018). Compellingly, OA has been observed in recordings 
from human peripheral nerves, and is correlated with self-reports of ongoing pain in patients 
with peripheral neuropathy or fibromyalgia (Ochoa et al., 2005, Orstavik et al., 2006, 
Kleggetveit et al., 2012, Serra et al., 2012, Serra et al., 2014). 
 Many of the C-fiber neurons exhibiting SA are responsive to the TRPV1 activator, 
capsaicin, suggesting the hyperexcitable cells are nociceptors (Bedi et al., 2010). In fact, 
application of capsaicin to isolated DRG neurons leads to repetitive firing patterns reminiscent 
of SA, and the firing activity is enhanced post-SCI (Wu, 2013). Inhibition of TRPV1 in SCI 
rats also reverses pain-like behaviors (Rajpal et al., 2007, Wu, 2013). As TRPV1 channels are 
almost exclusively expressed in nociceptors (Lauria, Cavanaugh et al., 2011), the data taken 
together suggest that SCI-induced nociceptor SA plays a major role in the maintenance of 
chronic pain. A study by Yang, et al. (Yang et al., 2014) lends further evidence for the 
contribution of primary sensory neurons to chronic pain maintenance. Here the authors show 
that knockdown of the Nav1.8 channel, which is only expressed in peripheral somatosensory, 
8 
 
but not central, neurons, mitigates both the SCI-induced SA and the pain-like behaviors (Yang 
et al., 2014).  
Based on the above studies, one may conclude that SCI-induced chronic pain is at least 
partially maintained by continuous input from peripheral, hyperactive primary afferent C-
fibers, and that this hyperactivity is due to persistent alterations in signaling pathways which 
affect ion channel function. However, what are the signaling pathways underlying this 
hyperexcitability and resulting chronic pain? Cyclic adenosine monophosphate (cAMP) to 
protein kinase A (PKA) signaling has been extensively studied for its role in maintenance of 
nociceptor hyperexcitability after peripheral inflammation or injury (Taiwo et al., 1989, 
Ferreira et al., 1990, Villarreal et al., 2009), and a study by our group shows a requirement for 
cAMP signaling through an AKAP150-AC-PKA signalosome to maintain this 
hyperexcitability in DRGs isolated from SCI rats (Bavencoffe et al., 2016). 
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Figure 2. The hyperactive, spontaneously active state is driven by the combined effects of three 
nociceptor intrinsic mechanisms: sustained depolarization of resting membrane potential 
(RMP), a decrease in action potential threshold, and an increase in amplitudes of depolarizing 
spontaneous fluctuations (DSFs).  
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1.3 cAMP signaling through the Downstream Effectors PKA and EPAC 
cAMP and Protein Kinase A (PKA) signaling are often considered synonymous (with 
a role for cyclic nucleotide gated ion channels, or CNGs and HCNs) (Taiwo and Levine, 1991, 
Malmberg et al., 1997, Aley and Levine, 1999).  cAMP is a prototypic secondary messenger; 
a cell is stimulated by extracellular ligand binding to G protein coupled receptors (GPCRs) to 
activate G proteins, which in turn promotes the conversion of ATP to cAMP by adenylyl 
cyclase (AC). Increased cAMP signals to downstream effectors, which in mammals includes 
PKA and EPAC (de Rooij et al., 1998, Kawasaki et al., 1998, Taylor et al., 2013), as well as 
the HCNs and CNGs (Zufall et al., 1997), the popeye domain containing (POPDC) proteins 
(Schindler and Brand, 2016), and the cyclic nucleotide receptor involved in sperm function 
(CRIS) (Krähling et al., 2013). For example, the well-studied prostanoid PGE2 interacts with 
the prostaglandin receptor EP4, a member of a subclass of GPCRs. Multiple studies have 
shown PGE2 injection into rodent hindpaws leads to transient mechanical hyperalgesia, which 
is dependent on cAMP/PKA signaling (Ferreira and Nakamura, 1979, Chen et al., 1999, Wang 
et al., 2007a, Eijkelkamp et al., 2010). However, the ubiquity of cAMP necessitates additional 
regulatory mechanisms to ensure the extracellular PGE2 signal leads to the appropriate cellular 
response.  
The specificity of cAMP signaling is modulated by its precise localization by ACs, 
phosphodiesterase (PDEs), and A-kinase anchoring proteins (AKAPs) (Esseltine and Scott, 
2013). ACs may be targeted to specific loci within mammalian cells or be tethered to AKAPs, 
which act as signalosomes to bring together the pertinent cAMP signaling components. In 
addition, PDEs degrade cAMP to reduce diffusion throughout the cell. The multiple 
mechanisms allow for precise, localized cAMP signaling, which promotes the appropriate cell 
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response despite the vast array of possible activating factors and downstream branching 
signaling cascades.  
As mentioned above, a study by our group showed a requirement for an AKAP150-
AC-PKA complex to maintain nociceptor hyperexcitability in DRGs isolated from SCI rats, 
along with a novel alteration in AC signaling (Bavencoffe et al., 2016). RNA sequencing data 
acquired from the same rat model of contusive SCI suggest that EPAC1 is upregulated after 
SCI, indicating that the nociceptor hyperexcitabilty and chronic pain behavior maintained by 
cAMP-PKA signaling might have an additional cAMP-EPAC mediated component 
(unpublished).   
In 1998 the cAMP effector exchange protein activated by cAMP (EPAC) was discovered 
(de Rooij et al., 1998, Kawasaki et al., 1998) and consequently shown to function in many 
roles previously ascribed solely to PKA. As suggested by its name, EPAC is a guanine 
exchange factor for the Ras family members Rap1 and Rap2 (though it can also interact with 
other small GTPases) and is activated by cAMP (de Rooij et al., 1998, Kawasaki et al., 1998). 
The major work of this thesis attempts to define a role for EPAC in the maintenance of chronic 
pain and nociceptor hyperexcitability after SCI in multiple rodent models. 
 
1.4 What is known about the roles of EPAC1 and EPAC2 in pain signaling? 
Evidence for a role for EPAC1 and EPAC2 in chronic pain 
The first evidence to suggest a role of EPAC in chronic pain proposed that cAMP to 
PKCɛ signaling is mediated by EPAC via PI-PLC and PLD, and not by PKA (Hucho et al., 
2005). The authors demonstrated that intraplantar injection of EPAC agonist 8-(4-
chlorophenylthio)-2′-O-methyl-cAMP (8-pCPT) in male rats leads to long lasting mechanical 
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hyperalgesia in vivo, which can be mitigated through inhibition of PKCɛ, PI-PLC, or PLD 
(Hucho et al., 2005). PKCɛ is known to play a role in nociceptor sensitization due to 
inflammation and peripheral neuropathies (Khasar et al., 1999, Aley et al., 2000, Dina et al., 
2001), and additional work shows a role for EPAC/ PKCɛ signaling in pain maintenance. DRG 
neurons previously challenged with the inflammatory mediator complete Freund’s adjuvant 
(CFA) will show an enhanced P2X3-mediated ATP current after another, secondary 
inflammatory insult. The enhanced response is dependent on EPAC/ PKCɛ signaling (Wang et 
al., 2007b). Interestingly, in uninjured DRG neurons the P2X3R mediated current is mediated 
by PKA only (Wang et al., 2007b). This parallels the change observed in inflammatory priming 
models used to study the transition from acute to chronic pain; the first inflammatory insult 
leads to short-lived, acute pain, mediated by cAMP-PKA signaling, while a second insult at 
least one-week later begets persistent chronic pain, maintained by EPAC signaling (Wang et 
al., 2013). Treatment with the EPAC specific inhibitor ESI-09 mitigates the inflammatory 
mechanical hyperalgesia (Wang et al., 2013, Singhmar et al., 2016).  
However, the role of EPAC may be slightly more complicated, as there are two main 
isoforms in vertebrates, with various levels of expression throughout the body. EPAC1 is 
encoded by Rapgef3 in mouse and EPAC2 by Rapgef4, which can actually give rise to three 
variants (EPAC2 in this thesis refers to the main isoform EPAC2A; there also exists an adrenal 
specific EPAC2B and liver specific EPAC2C in mouse; there are validated splice variants in 
humans as well but the specifics are unknown) (Navegantes et al., 2000, Ueno et al., 2001, 
Robichaux and Cheng, 2018). EPAC1 is ubiquitously expressed in mice with particularly high 
mRNA levels in brain, thyroid, kidney, ovary, and skeletal muscle (Kawasaki et al., 1998, Li 
et al., 2008), while EPAC2 is primarily expressed within the nervous system and adrenal glands 
(Ueno et al., 2001, Murray and Shewan, 2008). In human tissue, however, EPAC1 and 2 
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protein is found in almost every tissue examined, with the exception of ovary and oral mucosa, 
respectively (Robichaux and Cheng, 2018). 
The structure of EPAC is highly involved with its function as a guanine exchange factor 
(GEF) (de Rooij et al., 1998, Kawasaki et al., 1998). Both EPAC isoforms have a C-terminal 
catalytic domain and a N-terminal auto-inhibitory domain. The catalytic C-terminal contains a 
CDC-25HD domain, a Ras exchange motif (REM), and a Ras-association domain. The N-
terminal contains the high affinity cAMP binding domain (cAMP-B) and a Dishevelled, Egl-
10 and Pleckstrin domain (DEP) domain, as well as a second, low affinity cAMP-A binding 
domain present in only the EPAC2 isoform (Rehmann et al., 2006, Rehmann et al., 2008). 
Upon cAMP binding conformational changes relieve the auto-inhibition, stabilize the open 
configuration, and allow for GDP-GTP exchange activity. There is an ionic interaction 
between the cAMP-B helical bundle and CDC25HD, which is broken after cAMP binding. 
This allows conformational changes in the hinge region – between cAMP-B and REM – which 
stabilize the open configuration and allows for the GDP-GTP exchange activity (Rehmann et 
al., 2006, Rehmann et al., 2008). 
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Figure 3. Sequence and structural variations between EPAC1 and EPAC2 impart unique 
functions to each isoform. Both EPAC isoforms have a N-terminal auto-inhibitory domain 
containing the high affinity cAMP binding domain (cAMP-B) and a DEP domain, and a C-
terminal catalytic domain containing a Ras exchange motif (REM), a RA domain, and a CDC-
25HD domain. In EPAC2 the N-terminal also includes a second, low affinity cAMP-A binding 
domain. Several functions unique to each isoform are highlighted within this figure and in 
further detail within the text. These include the ability of EPAC1 to translocate to the nuclear 
membrane, and the potential for EPAC2 to play a role in exocytosis, among others.  
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Though 50% homologous, the differences between EPAC1 and 2 affect their structure 
and intracellular localization, which can potentially affect their respective roles in pain 
signaling (Figure 3). EPAC1’s subcellular localization is regulated by cAMP; as cAMP levels 
and localization fluctuates, so too do those of EPAC1 (Qiao et al., 2002, Ponsioen et al., 2009). 
Increased cAMP levels promote the plasma membrane association of EPAC1, while decreased 
levels promote distribution to the microtubule cytoskeleton (Qiao et al., 2002, Ponsioen et al., 
2009, Singhmar et al., 2016). After cAMP binding, EPAC1 translocation to the PM is 
dependent on conformational change in the DEP region, which exposes a 17 amino acid 
binding motif for phosphatidic acid (PA) (Li et al., 2011, Consonni et al., 2012). At the PM, 
EPAC1 can also associate with additional factors, such as activated ERM or radixin, for more 
precise localization (McClatchey and Fehon, 2009, Hochbaum et al., 2011). Here, activated 
EPAC1 can also sensitize the mechanoreceptor Piezo2, which may increase mechanically 
evoked currents (Eijkelkamp et al., 2013, Singhmar et al., 2016). This may be prevented by 
phospshorylation of serine-108 in EPAC1’s DEP domain by G protein-coupled receptor kinase 
2 (GRK2); as the DEP domain is responsible for EPAC1’s translocation to the PM, GRK2 
inhibits EPAC1’s GEF activity towards Rap1 not through inhibiting the conformational change 
to the active state but by blocking translocation to the PM (Eijkelkamp et al., 2013, Singhmar 
et al., 2016). Conversely, EPAC2 translocates proximal to the PM through its RA domain, not 
the DEP domain (Li et al., 2006). Differences in the EPAC2 RA domain allows EPAC2 to 
interact with Ras-GTP, independent of cAMP binding. Ras-GTP regulates EPAC2’s PM 
translocation, and is required for cAMP signaling through EPAC2 to Rap (Li et al., 2006, Liu 
et al., 2008, Alenkvist et al., 2017). 
EPAC1 can also localize to the nuclear membrane through interaction with Ran, 
RanBP2, importin B1, and nucleoporins 98 and 205 (Gloerich et al., 2011). RanBP2 interacts 
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with the amino acid 764-838 motif in CDC25-HD in EPAC1, and antagonizes EPAC1 by 
sequestering it at the nuclear membrane (as can importin B1) (Gloerich et al., 2011, Baameur 
et al., 2016). This interacting amino acid motif is conserved within EPAC2, but sterically 
blocked by the additional CNB-A domain (Aumo et al., 2010). The EPAC2B isoform, 
expressed in mouse adrenal glands, does not have the CNB-A domain, and thus localizes to 
the cytosol and the nuclear pore in a manner similar to EPAC1 (Niimura et al., 2009, Aumo et 
al., 2010, Parnell et al., 2015).  
Additionally, while the second low-affinity cAMP binding domain is not present in 
EPAC1 and is dispensable for PM trafficking in EPAC2, it is essential for EPAC2 clustering 
at granule docking sites in β-cells, and possibly in neurons (Alenkvist et al., 2017). While a 
role for EPAC2 in exocytosis has been more widely studied in the context of insulin release 
from β cells, it has also been demonstrated in neurons (Shibasaki et al., 2004, Shibasaki et al., 
2007). There is evidence that EPAC2 can interact with the small G Proteins Rim1a and Rab3 
to bring vesicles closer to the PM, and that EPAC2 can promote redistribution of 
neurotransmission enhancing factor Munc13-1 (Ferrero et al., 2013, Ferrero et al., 2016).  
Multiple studies have suggested that EPAC1, but not EPAC2, plays a major role in 
persistent inflammatory and neuropathic pain in mouse models (Eijkelkamp et al., 2013, 
Singhmar et al., 2016). A rat postsurgical pain model reached the same conclusion, 
demonstrating an increase in EPAC1 alone within the DRG, and significant mitigation of pain-
like behavior after EPAC1 inhibition (Cao et al., 2016). However, other studies have shown 
only an increase in EPAC2 expression in rats after CFA induced inflammation (Vasko et al., 
2014a). Conversely, work in the same rat CFA model showed an increase in both EPAC 
isoform expression levels in the DRG, and a reduction in pain-like behavior after inhibition of 
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either (Gu et al., 2016). To further complicate the literature, work in mice has suggested an 
ability of EPAC1 and 2 to compensate after knockout (Yang et al., 2012). 
 
1.5 Significance 
The roles of EPAC1 versus EPAC2 within chronic pain signaling remain unclear, 
though studies have argued for a focus on EPAC1, as EPAC1-/- mice do not develop 
mechanical hyperalgesia after CFA-induced inflammation or after L5 nerve transection 
(Eijkelkamp et al., 2013, Singhmar et al., 2016). Indeed, a majority of studies within the field 
attribute inflammatory or neuropathic pain to EPAC1 signaling only, despite increases in both 
EPAC1 and EPAC2 protein levels within the DRG after CFA or incision-induced 
inflammation (Wang et al., 2007b). EPAC2 is also more abundant in mature neurons, which 
control dendrite stability and outgrowth through elevated EPAC2 levels, while EPAC1 is 
downregulated in neurons after early development (Murray and Shewan, 2008), again 
suggesting a role for EPAC2 in mature neuron physiology.  
I hypothesize that both EPAC1 and EPAC2 contribute to the maintenance and 
development of SCI-induced chronic pain and nociceptor hyperexcitabilty, and need to be 
considered in development of future therapies. Thus, within this study we used two SCI rodent 
models to characterize the roles of EPAC1 and 2 in chronic pain signaling, employing a variety 
of behavior and electrophysiology tests. Using a T10 (thoracic) contusion SCI rat model, we 
employed electrophysiological methods to characterize the role of EPAC1 and 2 in promoting 
nociceptor hyperexcitability. Using a SCI mouse model of T9 contusion, I utilized an array of 
common behavior tests, including the von Frey filament and Hargreaves thermal test, to test 
the effect of EPAC2-/- and total EPAC inhibition on SCI pain like behaviors.  I also used a 
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modified testing paradigm within the operant mechanical conflict (MC) test, which may better 
reflect the complex experience of pain. Electrophysiological techniques were used to study the 
effects of EPAC isoform specific knockout or inhibition on SCI-induced nociceptor 
hyperexcitabilty. Additionally, we used two novel, recently published electrophysiological 
methods, including a measure of ongoing activity (OA) and a analysis method for 
quantification of transient depolarizing spontaneous fluctuations (DSFs) in membrane 
potential that contribute to nociceptor excitability (Odem et al., 2018).    
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Chapter 2: Materials and Methods 
 
2.1 Animals 
All procedures followed the guidelines of the International Association for the Study 
of Pain and were approved by the McGovern Medical School at UT Health and University of 
Texas MD Anderson Cancer Center Animal Care and Use Committees. Adult male Sprague-
Dawley rats (Envigo, USA) were used. After arrival at the McGovern Medical School, the rats 
(8-9 weeks old, 250-300g, 2 per cage) were allowed to acclimate to a 12-hour reverse light/dark 
cycle for at least four days before beginning experiments.  
Adult male and female C57BL/6 (Charles River, USA) wild-type and EPAC2-/- mice 
(Pereira et al., 2013) were housed within the McGovern Medical school animal facility and 
subsequently transferred at 6-8 weeks of age to a controlled environment where they were 
allowed to acclimate for at least 1 week before beginning experiments. 
 
2.2 Spinal cord injury procedures 
Rat SCI surgeries were performed as previously described (Bedi et al., 2010, Wu, 2013, 
Yang et al., 2014, Bavencoffe et al., 2016). Rats were anesthetized with an intraperitoneal (i.p.) 
injection of ketamine (60 mg/kg, Henry Schein, Dublin, OH), xylazine (10 mg/kg, Henry 
Schein, Dublin, OH), and acepromazine (1 mg/kg, Henry Schein, Dublin, OH), or with 
isoflurane (induction 4-5%; maintenance 1-2%, Isothesia, Henry Schein, Dublin, OH). A T10 
vertebral laminectomy was followed by a dorsal contusive spinal impact (150 kdyne, 1 s dwell 
time) using an Infinite Horizon Spinal Cord Impactor (Precision Systems and Instrumentation, 
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LLC, Fairfax Station, VA). Sham-operated rats received the same surgical treatment without 
the contusion. The analgesic buprenorphine hydrochloride (0.02 mg/kg in 0.9% saline 2 ml/kg; 
Buprenex, Reckitt Benckiser Healthcare Ltd., Hull, England, UK) and the antibiotic 
enrofloxacin (0.3 ml in 0.9% saline; Enroflox, Norbrook, Inc., Overland Park, KS) were 
injected i.p. twice daily for 5 days (buprenorphine) or 10 days (enrofloxacin). Manual bladder 
evacuations were performed twice daily until rats recovered neurogenic bladder voiding. Rats 
included in this study received a score of 0 or 1 for both hind limbs the day after surgery, as 
measured on the Basso, Beattie, and Bresnahan (BBB) Locomotor Rating Scale (Basso et al., 
1995). 
Mouse SCI surgeries were conducted as previously described (Herrera et al., 2008, 
Herrera et al., 2010). Briefly, adult female and male mice were anesthetized by inhalation of 
4.0% isoflurane and maintained by a mixture of 1.5% isoflurane, 30% oxygen, and air 
administered through a rodent ventilator (Harvard Apparatus, model 683, Holliston, MA) 
throughout the surgical procedure. Following laminectomy of the 9th thoracic (T9) vertebrae, 
a force-controlled contusion (60 kDyne, 1-second dwell time) was performed using an Infinite 
Horizon Spinal Cord Impactor. Sham-operated animals received the same surgical treatment 
without the contusion injury. For 2-3 days post injury, mice received twice daily subcutaneous 
injections of 0.9% saline to ensure proper hydration (0.5 cc) and twice daily subcutaneous 
injections of buprenorphine (0.02-0.1 mg/kg) for pain management. For 10 days post injury, 
mice received twice daily subcutaneous injection of Baytril (0.2-0.5 mg/ml) to prevent urinary 
tract infections. Manual bladder evacuations were performed twice daily for the duration of 
the study. Mice had free access to food and water. Mice included in this study received a score 
of 0 or 1 for both hind limbs the day after surgery, as measured by the Basso Mouse Scale for 
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locomotion (BMS) (Basso et al., 2006). Animals that could not resume a minimum normal 
activity level after injury were euthanized. 
 
2.3 Western Blot 
At 8-10 weeks post-surgery, mice (including naïve litter mates) were euthanized by 
inhalation of isoflurane followed by cervical dislocation and transcardial perfusion of ice cold 
PBS (Sigma-Aldrich, St. Louis, MO). 3 months post-surgery, sham and SCI rats, as well as 
age matched naïves, were euthanized by i.p. injection of an overdose of 
pentobarbital/phenytoin (0.9 ml of Euthasol, Virbac AH, Inc., Fort Worth TX) followed by 
transcardial perfusion of ice cold PBS. DRGs from mice and rats were harvested below T9 and 
T10 levels, respectively, and subsequently frozen in liquid nitrogen. DRGs were homogenized 
in SDS lysis buffer (1% SDS, 320 mM sucrose, 5 mM Hepes pH 7.4, 1 mM NaF, 1 mM PMSF) 
with protease inhibitor cocktail P8340 (Sigma-Aldrich, St. Louis, MO). The homogenates were 
centrifuged at 14,000 rpm for 5 minutes at room temperature and then heated to 100°C for 5 
minutes and stored at -80°C. Protein concentrations were determined by the BCA method 
(Pierce BCA Protein Assay Kit, ThermoFisher Scientific, Waltham, MA). Equal amounts of 
cell lysates were separated on 9% SDS-PAGE gels and transferred to a PVDF membrane. 
Membranes were blocked in 5% (w/v) nonfat milk prior to incubation overnight (4°C) in 
primary antibody. Primary antibodies included EPAC1 (1:1000; Cell Signaling; Cat# 4155), 
EPAC2 (1:1000; Cell Signaling; Cat# 4156), PKC (1:1000; Santa Cruz; Cat# sc-10800), anti-
actin (1:1000; Cytoskeleton; Cat# AAN01); and GAPDH (1:20,000; RDI; Cat#RDI-Trk5G4-
6C5). Membranes were incubated with anti-mouse or anti-rabbit IgG for 1 hour (room 
temperature) and developed using ECL or the Super Signal West Femto Kit (ThermoFisher 
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Scientific, Waltham, MA). GAPDH, Actin, and Stain Free imaging were used as a loading 
controls. Protein expression was then quantified by optical density using Image Lab software 
(Bio-Rad Laboratories, Version 5.2.1 Build 11). 
 
2.4 Dissociation and culture of DRG neurons.  
DRGs from mice and rats were harvested below vertebral levels T9 and T10, 
respectively. Ganglia were cleaned from roots and protective sheath before being transferred 
in high-glucose DMEM culture medium (Sigma-Aldrich, St. Louis, MO) containing trypsin 
TRL (0.3 mg/ml, Worthington Biochemical Corporation, Lakewood, NJ) and collagenase D 
(1.4 mg/ml, Roche Life Science, Penzberg, Germany). After 40 minutes incubation under 
constant shaking at 34°C, digested fragments were washed by two successive centrifugations 
and triturated with a fire-polished glass Pasteur pipette. Cells obtained were then plated on 
8 mm glass coverslips coated with poly-L-ornithine (Sigma-Aldrich, St. Louis, MO) in DMEM 
without serum or growth factors and incubated overnight at 37°C, 5% CO2 and 95% humidity. 
 
2.5 Recording from dissociated DRG neurons.  
Whole-cell patch clamp recordings were performed at room temperature 18-28 hours 
after dissociation using a MultiClamp 700B (Molecular Devices, San Jose, CA) or an EPC10 
USB (HEKA Elektronik, Lambrecht/Pfalz, Germany) amplifier. Patch pipettes were made 
from borosilicate glass capillaries (Sutter Instrument Co., Novato, CA) with a horizontal P-97 
puller (Sutter Instrument Co., Novato, CA) and then fire-polished with a MF-830 microforge 
(Narishige, Tokyo, Japan) to a final pipette resistance of 3-8 MΩ when filled with an 
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intracellular solution composed of (in mM): 134 KCl, 1.6 MgCl2, 13.2 NaCl, 3 EGTA, 9 
HEPES, 1 Mg-ATP, and 0.3 Na-GTP, which was adjusted to pH 7.2 with KOH and 300 mOsM 
with sucrose. Isolated small neurons with a soma diameter ≤ 30 µM were observed at 20x 
magnification on IX-71 (Olympus, Tokyo, Japan) or 40x on TE2000-U (Nikon, Tokyo, Japan) 
and Axiovert 200M (Zeiss, Oberkochen, Germany) inverted microscopes and recorded in a 
bath solution containing (in mM): 140 NaCl, 3 KCl, 1.8 CaCl2, 2 MgCl2, 10 HEPES, and 10 
glucose, which was adjusted to pH 7.4 with NaOH and 320 mOsM with sucrose. After 
obtaining a tight seal (>1 GΩ) when held at -60 mV, the plasma membrane was ruptured to 
achieve whole-cell configuration. Recordings were acquired with Patchmaster v2x90.1 
(HEKA Elektronik, Lambrecht/Pfalz, Germany) and Clampex v10.4 (Molecular Devices, San 
Jose, CA). The liquid junction potential was calculated at ~4.3 mV and not corrected in the 
recordings and measurements presented herein. 
 
2.6 Quantifying depolarizing spontaneous fluctuations 
Depolarizing spontaneous fluctuations (DSFs) were analyzed as previously described 
(Odem et al., 2018). Briefly, we used a custom program (SFA.py) to quantify irregular DSFs 
in patch recordings, which we imported as time and voltage coordinate data for 30-second 
periods from recordings obtained with PatchMaster (HEKA Elektronik) sampled at 20 kHz 
and filtered with a 10 kHz Bessel filter. The program used a sliding median function to 
calculate resting membrane potential (RMP) at each point and returned coordinates, 
amplitudes, and durations of identified action potentials (APs) and DSFs (minimum amplitude 
and duration 1.5 mV and 5 ms), as well as a continuous color-coded plot of membrane potential 
generated using the matplotlib library (Python) (Odem et al., 2018). Manual inspection of each 
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plot confirmed that each AP was generated by a suprathreshold DSF. We estimated the 
amplitude of the suprathreshold DSFs by 1) identifying the point at which the change in 
membrane potential began to accelerate immediately before the AP and 2) measuring the 
amplitude of the largest subthreshold DSF at RMP and during rheobase measurements (Odem 
et al., 2018). 
 
2.7 Pharmacological Agents 
EPAC2 inhibitor ESI-05 was synthesized as described in Chen et.al. (Chen et al., 2013). 
EPAC activator 8-pCPT-2-O-Me-cAMP-AM (007-AM) was purchased from Tocris 
Bioscience (Bristol, England, UK) and EPAC 1 inhibitor CE3F4 from Cayman Chemicals 
(Ann Arbor, MI).  Drugs were prepared in DMSO (Sigma-Aldrich, St. Louis, MO) at a 
concentration of 20 mM for ESI-05 and CE3F4 and 10 mM for 007-AM. Reagents were then 
diluted in extracellular recording solution at a minimum dilution factor of 1/1000. 
For in vivo studies ESI-09 was dissolved in ethanol (10mg/ml) and diluted 1:10 in 10% 
Tween80 in PBS. ESI-09 was sterile filtered before intraperitoneal injection at a dose of 10 
mg/kg (Gong et al., 2013). For in vitro studies ESI-09 was prepared in DMSO at a 
concentration of 50mM and the diluted in extracellular recording solution to 5 uM.  
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Figure 4. Timeline of Mouse Behavior Studies. WT and EPAC2-/- mice underwent a standard 
set of behavior tests over a 2 month period. (A) 6-8 week-old mice were tested to determine 
baseline behavioral values before receiving a T10 SCI contusion injury. After a 3 week 
recovery period, mice were re-tested using the same behavioral assays. At 5 weeks post SCI, 
mechanical sensitivity was again tested with and without in vivo pharmacological inhibition of 
EPAC by ESI-09. (B) Baseline behavior testing was performed over a 2 week period, and 
included the Elevated Plus Maze (EPM) anxiety test, rotarod motor coordination test, 
mechanical conflict (MC) test, von Frey (VF) mechanical sensitivity test, Hargreaves thermal 
sensitivity test, open field activity test, and evaluation of locomotor ability by the Basso mouse 
scale (BMS), in the order shown. (C) Three weeks post SCI, mice underwent the same series 
of behavior tests, with the exception of the EPM and rotarod, in the order shown. (D) Five 
weeks post SCI, VF was used to evaluate the effect of in vivo pharmacological inhibition of 
EPAC on mechanical sensitivity after SCI. On days 1-4, mice underwent VF testing in the 
morning and received i.p. injection of ESI-09 in the evening. VF testing continued for 6 
additional days after the final treatment.  
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2.8 Behavioral Testing 
Behavior tests were performed by the same blinded investigator throughout (Figure 4). 
Mice were allowed to acclimate to the behavioral testing room for 30-60 minutes in their home 
cages before beginning testing. Mice were acclimated with the investigator present. 
Mechanical Conflict (MC) Test 
A mechanical conflict (MC) test was used to assess voluntary avoidance of noxious 
probes as an operant measure of altered pain sensitivity (Figure 5). The commercially available 
MC test device (Mechanical Conflict-Avoidance System, Coy Lab Products, Grass Lake, MI, 
USA) consists of two rectangular chambers (each 16.5 cm wide by 21.5 cm deep by 15.25 cm 
high) connected by a narrow 30.4 cm long tunnel containing a dense array of sharp probes on 
the floor (Harte et al., 2016). We modified the tunnel floor for mice to a 30.4 cm by 3.8 cm 
array of 3 mm, more closely spaced, fine, blunt metal probes (tip diameter ~0. 63 mm). In each 
test, a mouse was placed in the darkened first chamber with the gate closed to prevent access 
to the tunnel. After 30 seconds the chamber was illuminated by a bright light emitting diode 
(LED) with a mildly aversive mean illuminance of 442 foot-candle at the compartment floor, 
meant to promote escape to the unlit chambers. After at least 15 seconds, when the mouse was 
facing the gate, the gate was lifted to allow free movement throughout the device for the 
remaining 3 minutes of the test. The test was video-recorded for subsequent analysis (Sony 
Handycam, HDR-XR260, recorded in HD). Videos were analyzed by a separate, blinded 
investigator for latency to the 1st step onto the probe floor, the total time on the probe floor, the 
latency to the first crossing of the probes (all four paws in the dark chamber), second crossing 
latency (front-paws re-entering the original chamber), and total number of crossings. Latency 
measurements always began when the gate was fully raised. In our preliminary testing we 
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observed that repeated trials significantly decreased the number of crossings and increased the 
latency to cross. Similar studies with rats suggested that a large component of the motivation 
to cross the aversive probes is the strong drive of rodents to explore an unfamiliar context. To 
reduce possible habituation to the MC device, we modified our procedure to allow the mice to 
experience the MC only twice, with a period of 3-4 weeks separating each exposure, to keep 
the test novel. Unlike previously published studies using the MC test, the mice had not 
experienced the probes before their first crossing. When crossing a second time (presumably 
motivated by innate exploratory drive), the mice had recently experienced the aversive probes 
and could exhibit voluntary avoidance behavior by delaying or avoiding a second crossing.  
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Figure 5. The operant Mechanical Conflict (MC) test procedure maximizes the innate 
exploratory drive. Mice are placed in the first chamber, where they are allowed to acclimate 
for 30 seconds with the gate closed and the light off.  The LED light is turned on and 
experienced by the mice for 15 seconds before the gate is lifted (though it may be lifted later 
to ensure the mice are facing the gate). The mouse crosses the tunnel into the dark chamber, 
experiencing the mechanical probes for the first time. The mouse may now continue to move 
freely through the MC device for the next 3 minutes. There are no familiarization pre-trials, 
thus keeping the test novel.  
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Von Frey mechanical sensitivity test 
Von Frey filaments were used to determine the 50% paw withdrawal threshold using 
the up and down method (Chaplan et al., 1994). Animals were placed in red plastic testing 
chambers (8.9 cm wide by 8.9 cm deep by 15.2 cm high) on a wire grid bottom and allowed to 
acclimate for 30 minutes with the investigator present. Von Frey filaments were applied for < 
1 second through the grid perpendicular to the plantar surface of the hindpaw with sufficient 
force to buckle against the paw, with the tester allowing 30 seconds between stimuli (starting 
with a bending force of 0.4 g; range: 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1.0, 1.4, 2.0, 4.0 g, North 
Coast Medical, Inc., San Jose, CA, USA). The subsequent filament force was increased 
following a negative response, or decreased following a positive response, with a total of 10 
stimuli per hindpaw. A positive response was recorded if the paw was quickly withdrawn, 
which was often accompanied by paw grooming or shaking behavior.  
Hargreaves heat sensitivity test 
The latency to withdrawal from a radiant heat stimulus was measured using the Plantar 
Analgesia Meter (IITC Life Science Inc., Woodland Hills, CA, USA) as described previously 
(Hargreaves et al., 1988). Mice were placed in red plastic testing chambers (8.9 cm wide by 
8.9 cm deep by 15.2 cm high) on a 30°C heated glass surface and allowed to acclimate for 30 
minutes with the investigator present. A light beam, set to an intensity 30% of its maximum 
value (found to evoke a positive response in 10 seconds at baseline in naïve mice), was aimed 
at the hindpaw plantar surface until evoking a positive response, or for a maximum of 20 
seconds to prevent tissue damage. The latency to evoke a positive response (brisk hindpaw 
withdrawal) was recorded and each hindpaw was tested 5 times, with a 5 minute interval 
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between stimuli. The median response latency was recorded after excluding the shortest and 
longest latencies.  
Elevated plus maze anxiety test 
The 40 cm high elevated plus maze (EPM) was used to measure differences in anxiety. 
It consisted of four, 12 cm wide arms: two enclosed by 40 cm high walls and two open 
(modeled upon the Stoelting Co’s EPM model, Wood Dale, IL). Individual mice were placed 
in the EPM center and allowed to move freely for 5 minutes. The test was video recorded and 
later analyzed for time spent in the open versus closed arms, as previously described (Pellow 
et al., 1985, Acharjee et al., 2013, Nyuyki et al., 2018).  
Rotarod motor coordination test 
The rotarod was used to assess coordination in mice, as described previously (Rozas et 
al., 1997). Mice were placed on the rotating rod (Model ENV-576M, Med Associates, Georgia, 
VT) facing the direction opposite to the rotation. Mice underwent 3 preliminary training tests 
spaced 10 minutes apart. Mice must be able to stay on a rod rotating at 4 rpm for 60 seconds 
before moving past training. During the actual test, mice were placed on a rotating rod 
accelerating linearly with time from 4-40 rpm over the course of 5 minutes. The fall latency 
was recorded automatically by photobeam sensors, with the maximum time being 5 minutes. 
Mice underwent three trials spaced 15 minutes apart.  
Open field activity measure 
The open field apparatus (OFA) (ENV-515, Med Associates, Inc., St. Albans, VT) 
consists of an activity chamber (43.2 cm wide by 43.2 cm deep by 30.5 cm high) with 16 
infrared transmitters and receivers evenly positioned around the chamber’s periphery. Mice 
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were placed in the activity chamber and allowed to move freely for 25 minutes, and data were 
collected by the software provided with the OFA. The OFA software registers movements 
within the chamber by recording photo beam interruptions. We analyzed the first 5 minutes 
within the chamber for ambulatory distance traveled and average velocity. 
 
2.9 Statistical Analysis 
Data are presented as mean ± SEM or incidence (% of sampled neurons). P<0.05 is 
considered statistically significant. All data sets were tested for normality by the Shapiro-Wilk 
test. Normally distributed data were tested with the parametric t-test or 1-way ANOVA, 
followed by the Holm-Sidak method of pairwise comparison. Non-parametric tests included 
the Mann-Whitney U test or Kruskal-Wallis test, followed by Dunn’s test for each pair-wise 
comparison. Data reported as incidence were compared by Chi square or Fisher’s exact test 
when appropriate. Bonferroni corrections were made after multiple comparisons. Statistical 
analyses were conducted using SigmaPlot (Systat Software, Inc., San Jose, CA) and Prism 
v7.04 (GraphPad Software, Inc., La Jolla, CA, USA). 
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Chapter 3: Results 
 
3.1 Rationale 
Chronic pain affects over 25 million Americans yet the underlying mechanisms 
promoting and maintaining it are not fully understood (Nahin, 2015). Often resulting in a 
drastic drop in quality of life, chronic pain is a complex syndrome associated with multiple 
inflammatory and neuropathic pain states (Finnerup and Baastrup, 2012, Finnerup, 2013). 
While 65-80% of spinal cord injury (SCI) patients report suffering from this condition, 
treatments remain inadequate, highlighting the necessity of defining new and accessible 
therapeutic targets (Siddall et al., 2003). 
Alterations occurring at the spinal and supraspinal levels have been a focus of multiple 
studies, with an emphasis on the effects of gliosis (Detloff et al., 2008) or loss of local 
inhibitory (GABAergic) tone (Meisner et al., 2010), which contribute to the maintenance of 
at-level and below level neuropathic pain after SCI. However, recent studies indicate an 
unexpected contribution of the peripheral nervous system, specifically a switch in nociceptors 
within dorsal root ganglia (DRG) at and below the contusion level to a persistent, 
hyperexcitable state (Bedi et al., 2010, Walters, 2012, Yang et al., 2014). This hyperactive state 
can be observed between 3 days and 6 months post injury, and arises from the combined effects 
of sustained depolarization of resting membrane potential (RMP), a decrease in action potential 
threshold, and an increase in amplitudes of depolarizing spontaneous fluctuations (DSF) 
(Odem et al., 2018). These three intrinsic mechanisms promote and maintain spontaneous 
activity (SA) after SCI and can also potentiate ongoing activity (OA) in nociceptors driven by 
extrinsic signals (Bedi et al., 2010, Yang et al., 2014, Odem et al., 2018). 
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Our previous study describing intracellular signaling mechanisms maintaining SCI- 
induced SA within the somata of small diameter nociceptors showed that the hyperactive state 
depends on prolonged activation of cAMP-PKA signaling within an intact A-kinase anchoring 
protein 150 complex, as well as an alteration in adenylyl cyclase regulation (Bavencoffe et al., 
2016). Recent work has identified an additional cAMP effector involved in pain development: 
exchange protein activated by cAMP (EPAC). Peripheral EPAC was shown to mediate 
hyperalgesia induced by peripheral application of epinephrine or cAMP (Hucho et al., 2005) 
and to augment sensory neuron excitability and sensitivity in vitro (Wang et al., 2007a, 
Eijkelkamp et al., 2013, Vasko et al., 2014a, Gu et al., 2016), as well as to induce hyperalgesia 
in vivo (Hucho et al., 2005, Gu et al., 2016).  However, between injury models, there are diverse 
changes in EPAC1 and 2 expression levels within the dorsal root ganglion (DRG). The role of 
EPAC1 versus EPAC2 within chronic pain signaling remains unclear, though many studies 
have argued for a focus on EPAC1, as EPAC1-/- mice do not develop mechanical hyperalgesia 
after CFA-induced inflammation or after lumbar 5 (L5) nerve transection (Eijkelkamp et al., 
2013, Singhmar et al., 2016).  
 
3.2 Activity of EPAC1 and 2 is required for spontaneous activity generated in dissociated rat 
nociceptors after spinal cord injury 
The major goal of our study was to determine the role of EPAC in maintaining an SCI-
induced hyperexcitable state in primary nociceptors. Presumptive nociceptors were selected 
on the basis of small soma diameter (≤ 30 µm) and nonaccommodating properties during 
activation by 2-s depolarizing currents at twice the rheobase value (Odem et al., 2018). 
Previous studies have shown that ~70% of nonaccommodating neurons sampled under our 
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conditions are nociceptors based on capsaicin sensitivity and/or binding of isolectin B4 (IB4) 
(Bedi et al., 2010, Bavencoffe et al., 2016). Consistent with these previous studies, 1-8 months 
after SCI we observed a SA incidence of 72% within small DRG neurons isolated from injured 
male rats, versus the low 14% incidence found within naïve animals (Figure 6A). The high 
incidence of SA was associated with a significant depolarization of the RMP (-49 mV in SCI 
versus -57 in naïve rats, Figure 6B), decrease in AP threshold (Figure 6C), and a lower 
rheobase (20 pA in SCI versus 60 pA in naïve rats, Figure 6D). 
Previous studies have shown that both EPAC1 and EPAC2 can augment excitability in 
isolated sensory neurons (Eijkelkamp et al., 2013, Vasko et al., 2014b). In nociceptors isolated 
from SCI rats, we found that pretreatment with either the EPAC1-selective inhibitor CE3F4 
(10 µM) (Courilleau et al., 2012, Sonawane et al., 2017) or the EPAC2-specific inhibitor ESI-
05 (5 µM) (Tsalkova et al., 2012) for 15 minutes before recording significantly decreased the 
incidence of SA, by 61% and 66%, respectively, and hyperpolarized RMP (Figure 6B).  Action 
potential voltage threshold in DRG neurons isolated from SCI rats was not significantly 
affected (Figure 6C), while the rheobase increased after CE3F4 treatment (Figure 6D). Neither 
drug had a significant effect on the incidence of SA, RMP, rheobase, or AP threshold in 
isolated DRG neurons from naïve rats (Figure 6). Analysis of DSFs showed that the largest 
amplitudes occurred at more depolarized RMPs in nociceptors isolated from SCI rats, with the 
largest amplitudes occurring at -45 mV (Figure 6E), as shown previously by Odem et. al. 
(Odem et al., 2018). Both CE3F4 and ESI-05 treatment significantly decreased DSF 
amplitudes at RMPs between -55 and -41 mV (Figure 6E). 
ESI-05 inhibits EPAC2 with an IC50 of 0.4 ± 0.05 in the presence of cAMP, while it 
had no effect on EPAC1 (Tsalkova et al., 2012). Previous work suggest ESI-05 may bind the   
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Figure 6. EPAC1 or EPAC2 activity maintains SCI-induced hyperexcitability in dissociated 
small diameter rat DRG neurons. Small DRG neurons (diameter ≤ 30µm) harvested from 
naïve and SCI animals below and at the T10 spinal level were recorded by whole-cell patch 
clamp 18-30 hours after dissociation. DRG neurons were pretreated with either 10 µM 
CE3F4 or 5 µM ESI-05 for 15-20 minutes before recording. (A) Inhibition of EPAC1 or 2 
attenuated SCI-induced SA incidence. The ratio above each bar denotes the number of 
neurons with SA/the number of neurons sampled. Statistical comparisons of SA incidence 
were made with Bonferroni-corrected Fisher’s exact tests on the indicated pairs. (B) 
Inhibition of EPAC1 or 2 reversed SCI-induced depolarization of RMP. (C) Inhibition of 
EPAC1 or 2 did not reverse SCI-induced depolarization of AP voltage threshold. (D) 
Inhibition of EPAC1 attenuated the SCI-induced increase in rheobase.  Data shown as mean 
± SEM. Overall significance determined with one way ANOVA (or Kruskal-Wallis for non-
parametric data), followed by multiple comparisons with Dunn’s method. Naïve vs SCI rats 
were compared by paired t-test (or Mann-Whitney U for non-parametric data). (E) Inhibition 
of EPAC1 or EPAC2 decreased the amplitude of DSFs recorded at rest in DRG neurons from 
SCI rats, especially at more depolarized initial RMPs. DSFs were quantified by an automated 
program which estimated RMP via a sliding median function and then identified small 
depolarizing fluctuations (greater than 1.5 mV in amplitude lasting >5ms). DSFs were binned 
according to their starting RMP. Data are represented as mean ± SEM. The indicated 
statistical comparisons were performed with 2-way ANOVA/Dummett test. Data collected 
by A. Bavencoffe and M.A. Odem. Analysis by S.C. Berkey and A. Bavencoffe. Figure by S.C. 
Berkey. 
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interface between the two cAMP binding domains to lock EPAC2 into an auto-inhibitory 
configuration, which could not occur in EPAC1 as only one of these domains is present 
(Tsalkova et al., 2012). Conversely, CE3F4 has about a 10 fold preference for EPAC1 over 
EPAC2 , and again acts non-competitively in the presence of cAMP to inhibit EPAC1 GEF 
activity towards Rap1 (Courilleau et al., 2012, Courilleau et al., 2013).  
These results suggest that EPAC1 and EPAC2 both play a role in maintaining 
nociceptor hyperexcitability after spinal contusion. SCI-induced SA is promoted by 3 general 
electrophysiological alterations known to be intrinsic to the soma (and are likely to also occur 
in peripheral terminals): depolarization of RMP, decrease in AP voltage threshold, and 
enhancement in the frequency of large DSFs that bridge the gap between RMP and AP 
threshold to trigger APs and produce SA (Odem et al., 2018). Two of these alterations appear 
to involve one or both EPAC isoforms. The SCI-induced depolarization of RMP was reversed 
by inhibition of either EPAC isoform (Figure 6B). Although a trend for EPAC1 inhibition to 
reverse the reduction in AP threshold by SCI was seen, this effect was not statistically 
significant with this sample size and no effect of EPAC2 inhibition was evident (Figure 6C).  
On the other hand, inhibition of either isoform eliminated the SCI-induced increase in DSF 
amplitude observed at relatively depolarized RMP levels (Figure 6E). 
As EPAC inhibition affected most of the intrinsic mechanisms within nociceptors that 
lead to hyperexcitability and SA after SCI, we asked whether EPAC activation in DRG neurons 
isolated from naïve animals would induce hyperexcitability similar to that induced by SCI. 
Pre-treatment for 10-30 minutes with EPAC activator 007-AM (10 µM) led to a significant 
depolarization of RMP, hyperpolarization of AP threshold and a trend for rheobase to decrease 
(Figure 7B, C, D). Moreover, 007-AM treatment significantly increased the DSF amplitudes 
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in neurons with RMPs between -45 and -41 mV, and when neurons were held artificially at -
45 mV (Figure 7F). Nonetheless, EPAC stimulation failed to increase the incidence of neurons 
with spontaneous activity (SA) at RMP or neurons exhibiting ongoing activity (OA) when 
artificially depolarized to -45 mV (Figure 7A, E). These data suggest that both EPAC isoforms 
are necessary for maintenance of nociceptor hyperexcitability after SCI, but their activity is 
not sufficient in nociceptors from naive rats to produce either SA or substantial OA when 
combined with extrinsic depolarization. 
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Figure 7. Activation of EPAC1 and 2 has a slight effect on DRG neurons isolated from naïve 
rats, depolarizing the RMP and hyperpolarizing AP voltage threshold. DRG neurons 
harvested from naïve rats were pretreated with 10 µM 8-pCPT-2-O-Me-cAMP-AM (007-
AM) for 10-15 minutes before recording. (A) EPAC activation did not significantly affect SA 
incidence within neurons isolated from naïve rats. The ratio above each bar denotes the 
number of neurons with SA/the number of neurons sampled. Statistical comparison of SA 
was performed with Bonferroni-corrected Fisher’s exact test. (B) EPAC activation 
significantly depolarized RMP (C) with a trend toward a reduction in rheobase (D) and a 
significant hyperpolarization of AP voltage threshold. Statistical comparisons of data 
(represented were mean ± SEM) were made by Mann Whitney U test. (E) EPAC activation 
did not significantly affect OA incidence. The ratio above each bar denotes the number of 
neurons with OA/the number of neurons sampled. Statistical comparison of OA was 
performed with Fisher’s exact test. (F) EPAC activation significantly increased the DSF 
amplitudes at rest only for cells exhibiting RMP values between -45 and -41 mV. DSFs were 
binned according to initial voltage. Statistical Comparison was performed by 2-way ANOVA 
followed by Sidak method. Each point represents a single DSF. Data collected by A. 
Bavencoffe and M.A. Odem. Analysis by S.C. Berkey and A. Bavencoffe. Figure by S.C. 
Berkey. 
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3.3 SCI-induced behavioral hypersensitivity is increased after SCI in both wild-type and 
EPAC2-/- mice 
Our finding in rats that SA was reduced by inhibition of either EPAC1 or EPAC2, 
combined with reports (Wang et al., 2007a, Gu et al., 2016, Matsuda et al., 2017) showing an 
increase in EPAC2 protein levels in the DRG after peripheral inflammation, and that PGE2-
induced nociceptor sensitization involves EPAC2 (Vasko et al., 2014), led us to hypothesize 
that EPAC2 in primary nociceptors plays a major role in maintaining chronic pain after SCI. 
To test this hypothesis, we transitioned to a mouse model of EPAC2 knockout (EPAC2-/-).  
We first confirmed that EPAC2-/- mice did not exhibit significant differences from 
wild-type mice in general behavioral functions (Srivastava et al., 2012, Lee et al., 2015):  
anxiety, as tested by time spent in the open arms of the elevated plus maze (EPM); 
coordination, as tested by latency to fall off the rotarod; and activity level, as tested by average 
velocity within an activity box (Table 1). Von Frey filaments and the Hargreaves heat 
sensitivity tests were used to establish basal mechanical and thermal sensitivity thresholds, 
respectively. The mechanical withdrawal threshold and the thermal withdrawal latency did not 
differ significantly between genotypes (Table 1).  
However, using the enhancement of brisk withdrawal reflexes as a measure of 
increased pain sensitivity is problematic, especially after SCI, as sensitization of hindlimb 
reflexes can be part of spastic syndromes and reflexive measures do not capture the 
motivational/affective dimensions of pain (Baastrup et al., 2010, Yezierski and Vierck, 2010). 
In contrast, the mechanical-conflict test is a paradigm in which mouse voluntary (operant) 
behavior reveals the aversiveness of a rough substrate they must cross to explore an unfamiliar 
setting and to escape from an aversive bright light (Harte et al., 2016, Pahng et al., 2017)(Odem 
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et al. submitted). When tested with the MC, naïve wild type and EPAC2-/- mice crossed the 
aversive probes a similar number of times, and spent about the same amount of time on the 
probes (Table 1). The first and second crossing latency was not significantly different between 
genotypes. The lack of a difference between the mouse genotypes in their reactions to the 
aversive probes is consistent with previous studies that found no clear behavioral differences 
between wild-type and EPAC2-/- mice (Srivastava et al., 2012, Lee et al., 2015), though a 
thorough analysis of pain-like behavior in EPAC2-/- mice has not been reported. 
Because the reflex-based sensitivity tests and the MC depend upon proper plantar 
placement, weight support, and stepping, we required the injured mice to recover to a BMS 
score which reflected sufficient motor function to readily cross the probes, defined as ≥3 on 
the BMS (Basso et al., 2006). One day post-surgery, sham mice exhibited complete locomotor 
function and received a score of 9, SCI mice exhibited slight to no ankle movements and 
received a score of 0 or 1 (Figure 8). Unexpectedly, at 3 weeks post-SCI, only the female mice 
showed sufficient recovery of plantar placement and stepping behavior, as indicated by a BMS 
score of 3-4. The male SCI mice only showed active movements of the ankle joints and thus 
received BMS scores of 2, regardless of genotype (Figure 8). Due to this gender difference in 
locomotor recovery, we only included female test subjects in the following behavioral 
experiments. 
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Table 1. No behavioral differences were seen between WT and EPAC2-/- mice pre-injury. 
Behavioral Tests were run pre-surgery with naïve WT and EPAC2-/- mice. Each value is the 
mean ± SEM followed in parentheses by the number of mice tested. Statistical tests include: 
paired t-test (t-test) and non- parametric Mann Whitney U test (MW). Data and Analysis by S. 
Rahman and S.C. Berkey. 
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Figure 8. Sex-specific differences in locomotor recovery post-SCI in mice. Gender 
significantly affected locomotor recovery post-SCI in mice. The BMS experiments were 
performed weekly after surgery, and significant differences between males and females were 
observed as early as 2 weeks post-injury. Mice were monitored during 4 minutes observation 
sessions, during which their movements were assessed according the previously published 
BMS scale and methodology (Basso et al., 2006). Statistical comparison was made using 2-
way RM ANOVA. Data collected by A. Bavencoffe and S.C. Berkey. Analysis by M.A. Odem 
and S.C. Berkey.  Figure by S.C. Berkey. 
  
46 
 
Three weeks after injury, female SCI WT mice showed a significant decrease in 
mechanical threshold for paw withdrawal as tested by von Frey filaments, but this decrease 
was not significantly different from the similar decrease seen in the sham control group (Figure 
9A). In addition, no change in heat sensitivity was found in SCI WT mice (Figure 9B). 
Knockout of EPAC2 did not alter the responses of SCI or sham-operated rats to the mechanical 
or radiant heat test stimuli. In contrast, the operant MC, which reflects affective-motivational 
and cognitive-evaluative dimensions of pain (Harte et al., 2016, Pahng et al., 2017)(Odem et 
al., submitted) revealed enhanced pain-avoidance behavior after SCI and no effect of EPAC2 
deletion. Both SCI wild-type and EPAC2-/- mice crossed the probes less often than sham 
animals (Figure 9C), and took significantly longer to complete the second crossing (Figure 
9D), indicating similarly increased pain-avoidance behavior in wild type and EPAC2-/- SCI 
mice. Together, these data indicate that SCI increases sensitivity to noxious but not innocuous 
mechanical stimuli under our conditions, and that the enhanced pain-avoidance behavior is not 
prevented by deletion of EPAC2. 
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Figure 9. SCI-induced increase in pain-like behaviors within both wild-type and EPAC2-/- 
mice, as shown by novel MC test. Post sham or SCI behavioral experiments were performed 
3-4 weeks after surgery. (A) SCI led to a significant decrease in the mechanical 50% 
withdrawal threshold in tested hindpaws of SCI WT and EPAC2-/- mice, and a trend towards 
a decrease in sham mice, as shown by von Frey filament testing. (B) Heat sensitivity was not 
significantly increased in SCI versus sham mice, as tested by the plantar analgesia meter set 
to 30% its maximum intensity. (C) SCI significantly decreased the total number of crossings 
made within the MC, and (D) increased the latency to the second complete crossing. Data are 
shown as mean ± SEM. T-test was used to compare WT sham to WT SCI mice, as well as 
WT SCI mice to EPAC2-/- SCI mice. Data and Analysis by S. Rahman and S.C. Berkey. 
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3.4 SCI-induced SA and depolarization-dependent OA are prevented by combined inhibition 
and knockout of both EPAC isoforms 
We had expected that EPAC2-/- mice would be protected against pain-like behaviors as 
an EPAC2 inhibitor was able to mitigate the SCI-induced effects in rat nociceptors. However, 
EPAC2-/- and WT mice demonstrated a similar enhancement of pain-avoidance behavior after 
SCI, suggesting that deletion of EPAC2 does not reduce SCI-induced hyperexcitability in 
mouse nociceptors. To explore potential explanations for this failed prediction in EPAC2-/- 
mice, we asked if both EPAC2-/- and EPAC1-/- mice exhibit an increased incidence of SA after 
SCI. 
Presumptive nociceptors isolated from WT mice 8-10 weeks after SCI showed a 
significant increase in the incidence of SA (Figure 10A, B). In addition, each of the three 
intrinsic electrophysiological alterations that promote SA were found: depolarization of RMP 
(Figure 10C), hyperpolarization of AP voltage threshold (Figure 10D), and increased DSF 
amplitude (see below). SCI-induced hyperexcitability also manifested as a decrease in 
rheobase (Figure 10E).  
SCI increased the mean DSF amplitude at RMP or when artificially depolarized (OA) 
to -45 mV (Fig. 11A). SCI also increased the number of large (≥8 mV) DSFs observed at 
RMP or when membrane potential was artificially depolarized to -45 mV. Large DSFs were 
especially prominent in neurons during SA and/or OA, which were common after SCI but 
not after sham treatment (Fig. 11B). The 8 mV minimum for large DSFs was defined 
functionally as the difference between the mean RMP and the mean AP voltage threshold 
(both measured after SCI) – a size that should often but not always trigger APs after SCI. All 
the APs generated during SA at RMP or during OA at -45 mV appeared to be triggered by 
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large DSFs, but to ensure that DSF amplitudes were measured precisely, only large 
subthreshold DSFs were included in this analysis. Deletion of EPAC2 did not alter the effects 
of SCI on electrical properties as compared to WT, except for the RMP, which was not 
significantly altered in neurons from EPAC2-/- mice (Fig. 10, 11).  
Previous work suggested that EPAC1, but not EPAC2, plays a major role in persistent 
inflammatory and neuropathic pain in rodent models (Eijkelkamp et al., 2013). In contrast, 
after SCI we found that EPAC1-/- mice showed significant enhancement in the incidence of SA 
similar to that found in WT and EPAC2-/- mice (Figure 10B). However, EPAC1-/- mice failed 
to show significant depolarization of RMP or hyperpolarization of AP threshold (Figure 10C, 
D). Recent work suggests EPAC1 and 2 may play redundant roles and be able to compensate 
for each other (Yang et al., 2012). This possibility was tested in the mouse SCI model by 
pharmacological inhibition of the complementary isoform in EPAC1 or EPAC2 knockout 
mice. Treatment of nociceptors isolated from EPAC2-/- SCI mice with the EPAC1 inhibitor, 
CE3F4, led to a significant decrease in the incidence of SA (Figure 10B). The converse 
experiment, using nociceptors from EPAC1-/- SCI mice with the EPAC2 inhibitor ESI-05, also 
caused a significant decrease in SA (Figure 10B). The AP voltage threshold (Figure 10D) and 
rheobase (Figure 10E) were not significantly affected by either treatment, although CE3F4 
treatment of SCI nociceptors from EPAC2-/- mice did further depolarize the RMP (Figure 10C).  
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Figure 10. Inhibition of both EPAC1 and 2 isoforms is necessary to mitigate SCI-induced 
hyperexcitability in dissociated mouse DRG neurons. Small to medium-diameter DRG 
neurons (≤ 30 µm) harvested from below and at the T9 spinal level were recorded by whole-
cell patch clamp 18-30 hours after dissociation. Neurons were pretreated with either vehicle, 
10-20 µM CE3F4 or 5 µM ESI-05 for 15-20 minutes before recording. (A) Representative 
10-second recordings obtained from non-accommodating neurons (presumptive nociceptors) 
at rest (I = 0). (B) Nociceptors isolated from EPAC1-/- or EPAC2-/- mice were not protected 
against increased incidence of SCI-induced SA; additional pharmacological inhibition of the 
complementary isoform was required to bring SA incidence towards a level comparable to 
neurons isolated from naïve/sham mice. The ratio above each bar denotes the number of 
neurons with SA/the number of neurons sampled. Statistical comparisons of SA incidence 
were made with Bonferroni-corrected Fisher’s exact tests on the indicated pairs. (C) SCI-
induced depolarization of the RMP in wild-type and EPAC2-/- mice; additional inhibition of 
the EPAC1 isoform was required to mitigate SCI-induced depolarization within neurons 
isolated from EPAC2-/- mice. (D) SCI-induced significant hyperpolarization of AP voltage 
threshold in wild-type and EPAC2-/- mice (trending within EPAC1-/- SCI mice); additional 
inhibition of the EPAC1 isoform did not cause a significant change in the SCI-induced AP 
voltage threshold hyperpolarization within nociceptors from EPAC2-/- mice. (E) SCI-induced 
a decrease in rheobase in wild-type and EPAC2-/- mice (trending within EPAC1-/- SCI mice); 
additional inhibition of the EPAC1 isoform did not cause a further significant change in the 
SCI-induced decrease in rheobase within nociceptors from EPAC2-/- mice.  Comparisons of 
data (mean ± SEM) were made by t-test (for wild-type data), or Kruskal-Wallis followed by 
Dunn’s method for pairwise comparisons. Data collected by A. Bavencoffe and M.A. Odem. 
Analysis by S.C. Berkey and A. Bavencoffe. Figure by S.C. Berkey.  
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Figure 11. SCI increases the amplitude of DSFs. DSFs were quantified by an automated 
program which estimated RMP via a sliding median function and identified depolarizing 
fluctuations >1.5 mV that lasted >5 ms. (A) SCI induced an increase in average DSF 
amplitudes recorded at RMP and when cells were depolarized to -45 mV in nociceptors 
isolated from wild-type and EPAC2-/- mice. Data are represented as mean ± SEM. (B) DSFs 
suprathreshold for generating action potentials have amplitudes ≥8 mV in mice. SCI induced 
a significant increase in the frequency of non-functional DSFs ≥8 mV in WT and EPAC2-/- 
mice at rest and when cells were depolarized to -45 mV. Statistical comparisons were 
performed with Kruskal-Wallis followed by Dunn’s method for pairwise comparisons. Data 
collected by A. Bavencoffe and M.A Odem. Analysis and figure by S.C. Berkey. 
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Interestingly, though there are significant differences in nociceptor hyperexcitability 
between sham and SCI mice of each genotype, the overall incidence of SA in mice after SCI 
increased to a lesser degree than in rats; mice of all genotypes showed an SA incidence of 
~40%, while rats showed closer to ~75% after SCI. While SA is generated solely by 
mechanisms intrinsic to nociceptors, SCI-induced OA occurring during artificial 
depolarization to -45 mV stems from intrinsic changes produced by SCI that only manifest as 
ongoing discharge when combined with extrinsic depolarizing input, such as occurs during 
inflammation (Odem et al., 2018). After SCI, the incidence of OA was significantly increased 
within WT, EPAC1-/-, and EPAC2-/- mice (Figure 12A, B). Furthermore, neither EPAC1 nor 
EPAC2 knockout mice were protected against SCI-induced increases in OA. Again, we asked 
if there was compensation or redundancy between EPAC1 and EPAC2. Treatment of 
nociceptors with an EPAC inhibitor in which the opposite isoform was deleted led to a large, 
significant decrease in the incidence of OA (Figure 12B). Together with the results 
summarized in Figure 9, this finding provides strong evidence that EPAC1 and 2 either have 
redundant functions in mouse nociceptors, or can be induced to compensate for the deleted 
isoform, leading us to examine whether SCI triggered corresponding changes in EPAC1 and 2 
protein levels.  
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Figure 12. Inhibition of both EPAC1 and 2 is necessary to mitigate SCI-induced OA in 
presumptive mouse nociceptors. To measure extrinsically driven OA, small DRG neurons 
were artificially depolarized to -45 mV by current injection for 30-60 seconds. DRG neurons 
isolated from EPAC1-/- or EPAC2-/- mice were not protected against SCI-induced OA; 
additional inhibition of the complementary isoform was required to reverse the effect of the 
injury. (A) Representative 10-second recordings obtained from neurons artificially held at -
45 mV. (B) The ratio above each bar denotes the number of neurons with OA/the number of 
neurons sampled. Statistical comparisons of OA incidence were made with Bonferroni-
corrected Fisher’s exact tests on the indicated pairs. Data collected by A. Bavencoffe and 
M.A. Odem. Analysis by S.C. Berkey and A. Bavencoffe. Figure by S.C. Berkey. 
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3.5 Treatment with the EPAC inhibitor ESI-09 led to widespread desensitization and 
electrophysiological silencing of nociceptors 
Our data suggests EPAC1 and 2 may play redundant and/or compensatory roles in 
nociceptor hyperexcitability. While we supported this conclusion in vitro using 
electrophysiological assays, we next attempted to show this mechanism in vivo.  Previous 
studies have shown that inhibition of both EPAC isoforms by ESI-09 can mitigate chronic 
pain-like behaviors after CFA treatment or paclitaxel-induced mechanical allodynia (Singhmar 
et al., 2016, Singhmar et al., 2018). ESI-09 is a competitive inhibitor for EPAC, and has been 
shown to inhibit both EPAC1 and 2 in vitro (Tsalkova et al., 2009, Tsalkova et al., 2012, 
Almahariq et al., 2013). We expected that i.p. injection of ESI-09 into WT or EPAC2-/- mice 
would mitigate SCI-induced chronic pain. Because we saw no significant differences in 
mechanical withdrawal threshold sensitivity post SCI, we decided to combine all treated 
animals into one group, regardless of genotype, to increase statistical power.  
We found a significant decrease in mechanical sensitivity in all treated mice, regardless 
of genotype, as measured by von Frey filaments (Figure 13A). The mechanical sensitivity 
decreased past the baseline seen in naïve mice, in direct disagreement with previous literature, 
which saw no ESI-09 induced effects on baseline sensitivity (Singhmar et al., 2016). However, 
use of ESI-09 in vitro caused the nociceptors isolated from both rat and mouse DRGs to 
become electrically inexcitable (Figure 13B); that is, efforts to induce an AP by stepwise 
increasing current injection into putative nociceptors failed to elicit any AP (representative 
recordings shown in Figure 13C). Cells were held at -60mV and received successive 
depolarizing pulses of 5 pA injected current in increments of 2sec, which never resulted in an 
AP in any neurons tested after ESI-09 treatment. We saw the electrophysiological response in 
SCI rats as well as SCI mice, regardless of phenotype. Treatment of EPAC1 or 2 knockout 
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mice with the EPAC1 specific inhibitor CE3F4 or the EPAC2 inhibitor ESI-05 (Figure 13) did 
not produce inexcitability, suggesting it was an effect due to the ESI-09 drug and not due to 
EPAC inhibition. As an additional control, we treated DRGs isolated from EPAC2-/- SCI mice 
with both CE3F4 and ESI-09 and again observed electrophysiological silencing of ESI-09 
(Figure 13B). This confirmed ESI-09 has non-specific, off target effects affecting the DRGs, 
which may have also affected the change in mechanical sensitivity (Figure 13A).   
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Figure 13. Inhibition of both EPAC1 and 2 by ESI-09 led to electrophysiological silencing of 
isolated DRGs. Post-SCI behavioral experiments were performed 5 weeks after surgery. (A) 
Repeated i.p. injection of ESI-09 over a 4 day period led to a significant decrease in mechanical 
sensitivity. Mechanical sensitivity was measured at 5 weeks Post-SCI by von Frey filament 
testing. SCI mice then received one i.p. injections of ESI-09 each day for 4 days. Mechanical 
sensitivity was measured over the 4 days, as well as an additional 6 days after the last treatment. 
(B) Treatment of isolated DRGs with 5 µm ESI-09 caused inexcitability in SCI rats and mice. 
There were no significant difference in the inexcitability produced by ESI-09 between species 
or genotype. The two other inhibitors of EPAC used in this study (CE3F4 and ESI-05) did not 
silence the DRGs. (C) Representative traces of the rheobase protocol. Cells were held at -60mV 
and received successive depolarizing pulses of 5 pA injected current in increments of 2sec. In 
cells treated with ESI-09 the rheobase protocol never resulted in an action potential. Data 
collected by A. Bavencoffe. Analysis and figure by A. Bavencoffe and by S.C. Berkey. 
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3.6 EPAC expression levels are unchanged in rat and EPAC2-/- mice post SCI 
Previous work in rodent models has published conflicting reports regarding EPAC 
expression levels in DRGs after various injuries: CFA-induced inflammation has been reported 
to increase only EPAC2 levels (Vasko et al., 2014a) or both EPAC1 and 2 protein levels in the 
DRG (Gu et al., 2016), while within a skin/muscle incision and retraction neuropathic model 
only EPAC1 protein is shown to increase within the DRG (Cao et al., 2016). Our 
electrophysiological data suggested both EPAC1 and 2 expression would be affected by SCI; 
however, within our neuropathic model of rat SCI, we found no significant change in EPAC1 
or 2 protein levels in the DRG between naïve and SCI rats (Figure 14A, B). Sham rats did not 
show significant differences from either naïve or SCI.  
Previous work in a mouse model of spinal nerve transection (SNT) (Eijkelkamp et al., 
2013), suggested SCI would result in an increase in EPAC1 expression levels within WT mice. 
However, again we did not observe significant increases in either EPAC1 or 2 protein levels 
after SCI in WT or EPAC2-/- mice (Figure 14C, D).  
  
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Figure 14. EPAC1 and 2 expression levels are unchanged after SCI in DRGs isolated from 
mice and rats. (A) EPAC1 and 2 expression levels were not significantly different in naïve 
versus SCI rats. (B) Bar graph represents band density for EPAC1 or EPAC2 levels 
normalized to total actin, with levels in the first lane (Naïve) set to 1. Naïve n= 4; SHAM 
n=5; SCI n=3. Comparisons of data (mean ± SEM) were made by One-way ANOVA or 
Kruskal-Wallis followed by Dunn’s method for pairwise comparisons. (C) EPAC1 and 2 
expression levels are not significantly different in wild-type sham versus SCI mice or 
EPAC2-/- naïve versus SCI mice. (D) Bar graph represents band density for EPAC1 or 
EPAC2 levels normalized to total protein as measured by stain free imaging, with levels in 
the first lane of each blot set to 1. Wild-type SHAM n=4; wild-type SCI n=5: EPAC2-/- naïve 
n=7; EPAC2-/- SCI n=6 Comparisons of data (mean ± SEM) were made by t-test. 
Comparisons of data (mean ± SEM) were made by t-test. Data and Analysis by S.C. Berkey. 
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3.7 Summary of Results 
Here we demonstrate the importance of both EPAC isoforms (EPAC1 and EPAC2) in 
maintaining a hyperexcitable state in nociceptors after SCI in two different rodent models. 
 In SCI rats, inhibition of either EPAC isoform is sufficient to mitigate SCI-induced 
hyperexcitabilty. We show that while EPAC expression levels were unchanged in rat DRGs 
after SCI, inhibition of either EPAC isoform significantly mitigates the hyperexcitable state. 
EPAC inhibition or activation had a significant depolarizing or hyperpolarizing effect, 
respectively, on RMP. As previously shown in rats (Odem et al., 2018) , SCI significantly 
increased DSF amplitude, especially at depolarized RMPs. The rise in DSF amplitude after 
SCI was reversed by inhibition of either EPAC isoform.  
In mice, we found EPAC2 knockout was not sufficient to mitigate SCI-induced pain-
like behavior in mice (though only female mice were tested). Our behavior testing included a 
novel design and test procedure within the MC, possibly providing a better measure of the 
complex experience of pain. EPAC1 or 2 knockout was not sufficient to decrease the 
significant enhancement in nociceptor hyperexcitability (SA and OA) after SCI. However, this 
may be due to a redundant and/or compensatory function between the two isoforms, though 
the mechanism is unclear. Pharmacological inhibition of the complementary isoform in 
EPAC1 or EPAC2 knockout mice led to a significant decrease in the incidence of SA and OA. 
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Chapter 4: Discussion and Future Directions 
 
4.1 Summary of Conclusions 
Developing effective chronic pain treatment is one of the great challenges facing 
healthcare today. The cost to the economy as well as individual sufferers is immense, and 
especially highlighted by the current opioid epidemic. To develop more effective treatment we 
need to better understand the mechanisms that maintain the chronic pain state. While cAMP 
signaling has been well studied for its role in chronic pain, most of its effects were thought to 
be mediated through PKA and cyclic nucleotide gated ion channels (Hingtgen et al., 1995, 
Kress et al., 1996, Gold et al., 1998, Wei et al., 2002, Kim et al., 2007, Emery et al., 2011). 
This work focuses on the role of an additional cAMP effector, EPAC, in chronic pain after 
SCI, with the hope that the mechanisms maintaining pain in this model may be relevant to 
other chronic pain types.  
The data reveal redundancy and/or compensation between EPAC1 and 2 within an SCI 
mouse model, and that inhibition of either isoform is sufficient in a rat SCI model to mitigate 
nociceptor hyperexcitability, highlighting the need for careful consideration when choosing a 
preclinical model.  This work additionally reveals gender specific differences in recovery after 
SCI, as well as the benefits of employing innovative analysis and testing techniques. 
 
4.2 Compensation and/or redundant functions for EPAC1 and EPAC2 in mice  
Behavioral experiments probing a wide spectrum of possible SCI-induced effects, from 
mechanical and thermal sensitivity to anxiety, did not reveal significant protective effects of 
EPAC2 knockout in mice. Analysis of electrophysiological data also indicated that knockout 
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of EPAC2 is not sufficient to protect against SCI-induced nociceptor hyperexcitability. 
However, neither is knockout of EPAC1. Instead, after knockout of EPAC1 or 2, the Epac2 
specific inhibitor ESI-05 or the Epac1 specific inhibitor CE3F4, respectively, significantly 
decreased the hyperexcitability. The data suggest redundancy and/or compensation between 
EPAC1 and 2, which is not unprecedented within the literature. A similar result was obtained 
within mouse hippocampal cells; knockout of both isoforms led to defects in spatial learning 
and memory, while knockout of only EPAC1 or 2 had no significant effect on behavior (Yang 
et al., 2012). The authors did not report a corresponding increase in the opposite EPAC isoform 
after knockout, as seen in our study (Yang et al., 2012).  
Portions of the literature point to straightforward mechanisms for compensation; for 
example, both isoforms are likely present in the affected nociceptor. EPAC1 is ubiquitously 
expressed while EPAC2 is highly expressed in adult neurons (de Rooij et al., 1998, Kawasaki 
et al., 1998, Murray and Shewan, 2008). In addition, both isoforms can localize to the PM and 
the cytoplasm, albeit through different interacting partners, and interact with similar 
downstream partners once there (de Rooij et al., 2000, Ponsioen et al., 2009, Grandoch et al., 
2010). The redundant/compensatory aspect is supported evolutionarily as well, as prokaryotes 
contain only one EPAC copy (closer to EPAC2), and eukaryotes contain both isoforms 
seemingly due to a gene duplication event (de Rooij et al., 2000).  
However, other aspects are harder to explain. EPAC2 plays a large role in exocytosis 
through interactions by its low affinity cAMP-A binding domain, which is not present in 
EPAC1 (Ozaki et al., 2000, Eliasson et al., 2003, Ster et al., 2007). Presumably, the defects in 
vesicle release would not only be an issue within the nervous system, but also within β-cell 
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granules and insulin release. Why there is not a larger phenotypic issue from EPAC2 knockout 
is an interesting question for further studies. 
It is also possible that though EPAC1 and 2 appear to be redundant and/or 
compensating in our assays, there may be some subtle defect that has yet to be parsed out. 
While EPAC1 and 2 overlap in function within the nociceptor, there may be small differences 
in their exact roles. This idea is supported by the first study to suggest compensation between 
EPAC1 and 2; though the authors concluded the EPAC2 KO mouse had no gross phenotype, 
they did see a subtle change in a measure of reversal learning (Yang et al., 2012). Indeed, closer 
analysis of our own data suggest a similar slight difference. We observed significant 
differences post SCI in rheobase and AP voltage threshold only from nociceptors isolated from 
EPAC2-/- mice, but not within those from EPAC1-/- mice. This suggests EPAC1 KO had a 
subtle protective effect after SCI, and may help to explain some of the controversy within the 
pain field regarding the contributions of EPAC1 versus EPAC2.  It is possible that within an 
inflammatory or peripheral nerve injury model, EPAC1-/- is sufficient to protect against the 
development of chronic allodynia (Eijkelkamp et al., 2013, Singhmar et al., 2016); however, 
our model suggests that both EPAC isoforms need to be accounted for when designing chronic 
pain therapies for certain injuries.  
I attempted to show in vivo redundancy between EPAC1 and 2 using an inhibitor of 
both EPAC isoforms, ESI-09, in WT and EPAC2 KO mice. While I did not observe a 
significant rescue of SCI-induced pain-like behavior in treated mice of either genotype, there 
are multiple possible reasons. Firstly, our study used only female mice (as discussed below), 
which have been shown in other models to be more susceptible to stress and age induced 
inflammation. The timeline of an SCI study is long, necessitated by multiple weeks of recovery 
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from injury and behavioral testing. Multiple animals were lost during recovery or after testing 
due to secondary SCI-problems (bladder infection, self-harm). It is possible the mice remaining 
at 5+ weeks post injury were those least affected by the SCI. Thus, the timeline created two 
confounding issues: a decreased cohort number made up of potentially the least 
affected/susceptible mice. 
However, we were surprised by the large decrease in mechanical sensitivity within all 
the mice after ESI-09 treatment, regardless of genotype. This was wholly unexpected, and not 
in line with previous reports. Our methods did differ slightly, as we used i.p. injection versus 
oral gavage (Singhmar et al., 2016), but that should not have had such a dramatic effect. Our 
preliminary electrophysiology studies of ESI-09 on isolated SCI nociceptors resulted in 
complete abolishment of SA. However, closer analysis showed that all treated cells had 
become inexcitable. This suggests to us that ESI-09 somehow silenced or harmed these 
nociceptors. The huge decrease in sensitivity seen in the behavior studies may be due to 
nociceptor silencing or harm, and thus a lack of peripheral sensation or input. Why this was 
not observed in other studies is unclear, as the dose was similar to other studies (Singhmar et 
al., 2016, Singhmar et al., 2018). It would be extremely interesting to employ other EPAC1 or 
2 specific inhibitors in future behavior studies to evaluate if the same 
compensation/redundancy is observed in vivo.  
 
4.3 Role for EPAC1 and EPAC2 in Rat 
 Although only the EPAC1 RNA levels were unchanged in rat DRGs post SCI, 
inhibition of either EPAC1 or 2 ameliorated the nociceptor hyperexcitable state. The observed 
change in EPAC1 expression adds to the conflicting reports in the literature; in a model of 
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CFA induced inflammation, Gu et.al. reports increased expression of both isoforms within the 
DRG (Gu et al., 2016), while previous work within the same rat inflammatory model suggested 
only EPAC2 levels increased (Vasko et al., 2014a). However, within a skin-muscle incision 
retraction neuropathic pain model, the authors also demonstrate an increase in only EPAC1 
expression within the DRG, and additionally showed EPAC1 inhibition mitigated pain-like 
behavior (Cao et al., 2016). 
 Some of the controversy may in fact arise from the clear contribution of both isoforms 
as seen in our electrophysiology data. Though both EPACs have a role and are normally 
expressed in nociceptors, how their functions overlap is still unclear. Depending on the severity 
of the injury, the pain state, and other confounding factors, the expression levels at the chosen 
end-point might differ. Additionally, EPAC1 has been embraced in the literature as the main 
isoform involved in chronic pain, possibly causing some studies to not consider or report on 
EPAC2 (Cao et al., 2016). 
 One of the advantages of electrophysiology assays is the ability to record data from an 
individual cell, which can be determined to be a nociceptor. And while done in vitro, the 
observed spontaneous activity and hyperexcitability has been convincingly linked to pain-like 
behaviors (Bedi et al., 2010, Wu, 2013, Yang et al., 2014). Therefore, the decrease in 
excitability after EPAC inhibition within nociceptors isolated from SCI rats suggests a role for 
both EPAC isoforms in SCI chronic pain. The decrease parallels that seen in previously 
published work examining the effect of PKA inhibition on nociceptors also isolated from SCI 
rats (Bavencoffe et al., 2016); however, EPAC inhibition resulted in profound depolarization 
of the RMP, while PKA inhibition had a much smaller effect. Conversely, EPAC activation by 
007-AM hyperpolarized nociceptors from naïve rats. Together the data suggest a role for 
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EPAC in regulation of the membrane potential. How this function for EPAC may crosstalk 
with PKA signaling to affect overall excitability is discussed further below. EPAC also affects 
DSF amplitude, another nociceptor intrinsic mechanism contributing to excitability. SCI 
increased DSF amplitude in rat nociceptors as seen previously (Odem et al., 2018), and this 
increase could be reversed by inhibition of either EPAC isoform or replicated by EPAC 
activation in naïve nociceptors held at -45 mV.   
 
4.4 An Operant Mechanical Conflict test reveals subtle SCI-induced effects on pain behavior  
Behavior tests measuring brisk withdrawal reflexes are problematic, as reflex behavior 
has been shown to increase due to spastic syndromes secondary to SCI, not just due to 
increased pain (Baastrup, Maersk-Moller et al. 2010, Yezierski and Vierck 2010). We 
addressed this concern with the MC, a conflict paradigm, which may better reflect the 
affective-motivational and cognitive-evaluative dimensions of pain (Harte et al. 2016, Pahng 
et al. 2017). As described in the methods, we modified the MC for use with mice; though we 
are not the first to do so (Zhou S 2012, Shepherd and Mohapatra 2018), we feel our method 
offered several advantages. Firstly, while our design did not employ different probe heights, it 
did allow extremely close spacing of the probes, which ensured mice would experience probes 
with every footfall, eliminating crossing strategies which utilize fitting the paws between the 
probes. We also believe the probes are causing hyperalgesia, as extensive preliminary testing 
was required to optimize the probe array to be aversive but not too aversive to naïve animals. 
For example, in early trials using the mechanical conflict device the probes were arranged in 
an alternating high low pattern, which resulted  in no or only one crossing by 5 out of 6 mice, 
across multiple trials.  Additionally, by narrowing and lowering the crossing chamber width 
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and height, we made it difficult for mice to turn around on the probes, which can confound the 
results, and impossible for mice to take a non-linear route, which would inherently increase 
the cross latency (though, unfortunately, this may frustrate attempts to compare our crossing 
time data with other studies).  
Thirdly, while photophobia in rodents is well documented, we found the aversive light 
to be only a weak stimulus, as in preliminary tests mice often did not cross from the light 
chamber at all, or showed no hesitation in crossing back towards the light. The high crossing 
rate observed suggested the mice were being driven instead by conflict between their innate 
exploratory drive and the noxious probes. Further, our early tests (employing a prolonged 
protocol) in which wild-type naive mice (n=5) were exposed to a probe free MC device 3 times 
within the same day revealed a significant decrease in crossing number that was dependent on 
the number of times a mouse experienced the test (p=0.002, One way RM ANOVA). By using 
the shortened test procedure described in our methods, we kept the MC novel and maximized 
the exploratory drive, making latency to the second cross the more informative measure; both 
WT and EPAC2-/- mice, whether naïve or SCI, experienced the probes, and potentially pain, 
on the first cross, and then weighed the two conflicting urges before completing the second 
cross. Preliminary work with EPAC1-/- mice (n=6) showed a similar result, as SCI caused a 
significant decrease in crossing number (p=0.005, t-test), in line with the potentially redundant 
functions of EPAC 1 and 2 seen in the electrophysiological assays. Previous work has shown 
an increase in crossing latency may be due to a desire to avoid mechanical stimuli while in a 
pain state (Harte et al. 2016, Shepherd and Mohapatra 2018). Therefore, the longer crossing 
times seen here in SCI mice may be indicative of avoidance behavior due to a pain state, which 
arguably requires higher-level processing and cognition.  
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4.5 Gender Specific Differences in Pain Signaling  
It is worth mentioning that the behavioral results reflect only the performance of female 
mice, as males do not recover sufficient locomotor function in a reasonable amount of time. 
We intended to use both sexes, and did so where possible in the electrophysiology and 
biochemical experiments, as conclusions based on solely male or female data sets are not 
applicable to half of the population (Mogil and Chanda, 2005). Unfortunately, preclinical 
studies within the pain field disproportionately rely on male models (Beery and Zucker, 2011), 
despite females being overrepresented in the human chronic pain patient population (Fillingim 
et al., 2009). 
Chronic pain in males is mediated in part by microglia activation, which act as the 
principal immune cells for the nervous system. Nerve injury triggers upregulation of purinergic 
P2X4 receptors, which, after ATP activation, can induce pain behavior and hypersensitivity 
through well characterized mechanisms. In short, P2X4 activates p38 MAPK, induces Ca2+ 
influx, and releases brain-derived neurotrophic factor to interact with TrkB receptors. This 
downregulates a neuronal potassium-chloride transporter to disrupt chloride transport, 
decreases inhibitory tone, and transforms the output of lamina I neurons.    
 While inhibition or ablation of microglia thus mitigates chronic pain in male models of 
chronic pain, there is no or little effect on female hypersensitivity (Sorge et al., 2015). Instead 
it is hypothesized that females employ adaptive immune cells, specifically T cells, rather than 
microglia to mediate chronic pain signaling (Mapplebeck et al., 2016). Interestingly, immune 
cells are recruited to the lesion site post SCI, and no doubt circulated throughout the 
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cerebrospinal fluid, to which the DRGs are exposed. Within female rats, SCI causes 
macrophage and T-cell infiltration into the DRGs (McKay and McLachlan, 2004). 
Further, estrogen was found to affect the cAMP/PKCɛ induced chronic hyperalgesia in 
surprising ways. While isoproterenol and 8-pCPT can activate PKCɛ to induce hyperalgesia 
(Hucho et al., 2005), estrogen could block this effect, seemingly at or downstream of EPAC 
(Hucho et al., 2006).  Additionally, estrogen application in vivo or in vitro could activate PKCɛ, 
an effect quickly abrogated by EPAC stimulation (Hucho et al., 2006).  While this study 
suggests a male SCI cohort would have been a better model to study EPAC signaling, our 
results did not show significant differences in nociceptor excitability between genders, 
suggesting additional mechanisms are at play. Bedi et. al. did show a greater overall incidence 
of SA after SCI within females versus males, however, the interaction of injury with sex was 
not significant (Bedi et al., 2010).  
Within our study, females recovered locomotor function within 4 weeks post injury, 
while males did not recover much more than limited ankle movement. The longer recovery 
time in males may have additional clinical implications, especially as recent studies have 
highlighted the detrimental effects of analgesic treatments too early or late after injury. Further, 
the disuse of affected limbs may further heighten the injury: immobilization can disturb 
mechano- and thermosensitivity in humans, while rat hindlimb immobilization alone can 
increase mechanical sensitivity (Terkelsen et al., 2008, Trierweiler et al., 2012). 
A handful of previous studies have also observed better recovery in female rodents 
after ischemic stroke (Payan and Conrad, 1977, Alkayed et al., 1998), spinal cord contusion 
(Hauben et al., 2002, Farooque et al., 2006), hypoxic brain injury (Stupfel et al., 1984), and 
closed head injury (Roof and Hall, 2000).  While the mechanism is still being elucidated, 
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estrogen has been proposed to confer a protective effect, potentially by increasing expression 
of the anti-apoptotic genes bcl-2 and bcl-x (Yune et al., 2004, Farooque et al., 2006). However, 
the protective effect was lost in a model of moderate SCI employing nude mice, suggesting 
estrogen’s protective effect is T-cell dependent (Hauben et al., 2002). How this potential T-
cell dependent protective effect of estrogen on recovery may interplay with the role of T-cell 
dependent pain signaling in females would be a fascinating area for future study.  
 
4.6 EPAC and PKA Signaling in a Chronic Pain Context 
The literature suggests that biased cAMP signaling towards either PKA or EPAC/PKCɛ 
underlies the transition from an acute to chronic pain state, respectively (Wang et al., 2007b, 
Eijkelkamp et al., 2010, Huang et al., 2015). For example, PGE2 potentiates P2X3R-mediated 
ATP currents within DRGs, mediated by PKA signaling downstream of the EP3C receptor 
coupled Gαs (Gu et al., 2016). However, if PGE2 is given as a secondary inflammatory insult 
after CFA, EPAC mediates and enhances the PGE2 induced P2X3R current (Gu et al., 2016).   
However, our results highlight the possible interplay between the two cAMP sensors 
in chronic pain; in nociceptors isolated from naïve rats, EPAC inhibition resulted in the same 
decrease in excitability as seen after PKA inhibition from previous work, but had a greater 
effect on RMP (Bavencoffe et al., 2016).  It is probable that while these two cAMP-dependent 
signaling pathways can affect the same ligand and voltage gated ion channels, they do so in 
diverse contexts and through divergent localization mechanism, to affect different components 
of nociceptor hyperexcitability.  
cAMP was the first secondary messenger implicated in nociceptor sensitization, and, 
besides limited signaling through CNGs, PKA was considered the major cAMP effector. 
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However, cAMP signaling though either PKA or EPAC can promote sensitization through 
regulation of voltage and ligand gated ion channels. For example, TRPV1 and TTX-R Na+ 
channels are strongly implicated in nociceptor sensitization, and cAMP signaling through PKA 
or EPAC can influence either channel. PKA may directly phosphorylate TRPV1 to prevent its 
desensitization (Bhave et al., 2002), while EPAC mediates cAMP to PKCɛ signaling to 
indirectly effect sensitization of TRPV1. Other examples of synergy between PKA and EPAC 
have been published previously (Hewer et al., 2011, Yu et al., 2017), including one proposing 
cooperative roles in neuron sprouting and neurite extension in the DRG after SCI (Wei et al., 
2016). It’s easy to imagine how an increase in activated nociceptors resulting in additional 
excitatory synapses could play a role in promoting chronic pain.  
Both PKA and EPAC have also been implicated in the regulation of intracellular Ca2+ 
levels, which markedly change within DRGs after inflammatory or neuropathic injury (Sah 
and Louise Faber, 2002, Bourinet et al., 2014). Work in pancreatic cells has shown EPAC 
mediates Ca2+ induced Ca2+ release (CICR) from intracellular stores, possibly through 
synergistic EPAC/Rap1 modulation and PKA sensitization of ryanodine receptors (RyRs) 
(Kang et al., 2003). This could potentially occur within nociceptors as well, as EPAC2 
activation in cultured cerebellar granule cells also mobilizes intracellular Ca2+ through Rap and 
p38 activation (Sah and Louise Faber, 2002, Ster et al., 2007). The resulting rise in intracellular 
levels promotes activation of calcium sensitive big potassium (BK) channels, which play a role 
in regulation of the AP duration and repetitive firing (Sah and Louise Faber, 2002, Ster et al., 
2007). BK channel regulation by PKA has been well characterized previously (Schubert and 
Nelson, 2001, Wang, 2008), providing another example of the overlap in EPAC and PKA 
signaling targets involved in nociceptor excitability.  
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4.7 Future Directions 
 Here we have shown a role for EPAC1 and 2 in maintaining hyperexcitability of 
presumptive nociceptors that promotes chronic pain. As knockout of either EPAC1 or 2 does 
not seems to disrupt normal development, both isoforms are good potential drug targets.  
However, to develop the most effective therapies, future efforts should focus on cAMP 
to EPAC signaling in the context of discrete localization mechanisms. Though some 
mechanisms of EPAC trafficking to specific loci are known, such as the role of the DEP 
domain in PM targeting of EPAC1, much remains to be elucidated (de Rooij et al., 2000, 
Ponsioen et al., 2009, Grandoch et al., 2010). cAMP signaling is well known to depend upon  
scaffolding of upstream and downstream pathway components by AKAPs, yet in neuronal 
cells there is almost nothing know about potential EPAC interactions (Nijholt et al., 2008). No 
doubt some of the differences in mechanisms targeting EPAC1 and 2 to the PM or nuclear 
membrane result in divergent localization to AKAPs or additional organizing platforms such 
as lipid rafts.  
Our data suggests that EPAC1 and 2 can act in a redundant and/or compensatory 
manner in mice and within rats. Additional work will be required to realize which model gives 
a closer estimate of the role of EPAC in human pain pathways. However, understanding which 
signalosomes EPAC interacts with will help illuminate EPAC1 and EPAC2’s respective roles 
within specific signaling networks. Further studies might also make use of Rap1 KO mice to 
investigate whether similar SCI-induced effects are observed (Pan et al., 2008). Use of these 
animals might help to tease apart the specific roles EPAC1 and 2 play, as both isoforms exhibit 
GEF activity towards Rap1 but also act through additional, unique signaling pathways.  
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 Additionally, distinct roles for EPAC1 and 2 in neuron development and mature repair 
programs have been suggested, respectively, based on fluctuations in protein expression levels 
(de Rooij et al., 1998, Kawasaki et al., 1998, Murray and Shewan, 2008). It is likely that the 
EPAC2 mediated programs for repair and regrowth after SCI are distinct from those involved 
in development; however, a better understanding of how each isoform acts in it respective role 
could help to delineate differences between complete neuron growth during development and 
the partial regeneration observed after injury in adults. Therapies that could account for these 
differences might help to improve current efforts aimed at regenerating injured nerves or spinal 
cord.  
 In conclusion, this work shows an important role for both EPAC1 and EPAC2 in 
chronic pain pathways, highlighting the need for future studies to consider both isoforms.   
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